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ABSTRACT 
Tangi L. Smallwood: The genetic architecture of atherosclerosis and the atherosclerosis-
associated metabolite trimethylamine-N-oxide in the diversity outbred mouse population 
 (Under the direction of Brian J. Bennett) 
Inbred mice exhibit strain-specific variation in susceptibility to complex diseases which 
renders them useful for dissecting the genetic architecture of these traits. Traditional quantitative 
trait locus (QTL) mapping studies using inbred strains often identify large genomic regions 
containing many genes and require extensive follow up studies to identify the causal genes 
underlying the associations. Alternatively, the use of recently developed multi-parent outbred 
mice designed to be informative for QTL mapping, such as the Diversity Outbred (DO) mouse 
population, can expedite the identification of causal genes and variants associated with complex 
diseases. Here, we used DO mice to study the genetic architecture of atherosclerosis and multiple 
risk factors associated with this complex disease. We fed 292 female DO mice either a high-fat, 
cholesterol-containing diet to induce atherosclerosis or a low-fat, high-protein control diet for 18 
weeks. We then quantified multiple metabolic phenotypes before and after dietary treatment and 
measured aortic lesion size in the mice after dietary treatment. We performed linkage mapping 
for these quantitative traits using a linear regression model based on reconstructed founder 
haplotypes. The additive haplotype model used produces estimates of the effects of the founder 
alleles which can be used to inform follow up studies and to identify the causal variants 
underlying the QTL. Among our highly significant results, we identified QTL associated with 
atherosclerosis, triglycerides, cholesterol, choline, trimethylamine-N-oxide, blood urea nitrogen, 
and insulin resistance in this cohort of DO mice. These results demonstrate the value of the DO 
population to improve mapping resolution and to aid in the identification of potential therapeutic 
targets for complex diseases.  
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CHAPTER I. INTRODUCTION 
ATHEROSCLEROSIS  
Cardiovascular diseases (CVDs) are a group of diseases that affect the heart and blood 
vessels and it is estimated that CVDs kill more people annually in the United States than any 
other disease [1]. Based on the most recent census of death certificate data, deaths due to CVDs 
in the US account for an estimated 26% of all deaths [2, 3]. Additionally, though the standards of 
quantification by recorded cause of death vary worldwide, is has been estimated that CVDs are 
the leading cause of morbidity globally as well [4].  
The most common cause underlying CVD is atherosclerosis, which accounts for 25-30% 
of cardiovascular disease-related deaths [5]. It is important to note that atherosclerosis is a 
progressive disease which is present to some extent in 2 out of every 3 Americans under the age 
of 35 [6]. While atherosclerosis is a prevalent pathological condition that often leads to fatal 
adverse cardiovascular events such as heart attack or stroke, it develops asymptomatically in 
young individuals [7-9]. Therefore, it is important to identify early predictive biomarkers for 
implementation of behavioral modifications and therapies to prevent the progression of the 
disease.  
At a molecular level, atherosclerosis is a result of endothelial dysfunction. It is initiated 
by localized damage to the endothelial cells lining the arterial wall or by the presence of oxidized 
LDL inside the vessel wall [10].  Injury to the endothelial cells includes not only loss of cells at 
the site of injury, but can result from a variety of processes that influence endothelial cell 
function independent of the loss of endothelial cells [11]. This begins a cascade of events that 
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ultimately results in macrophage recruitment and aggregation at the site of LDL deposition [12]. 
As macrophages engulf the accumulating LDL, they grow in size and become lipid-filled foam 
cells.  An atherosclerotic plaque of this type does not impede blood flow through the vessel and 
is referred to as a fatty streak. In advanced lesions, as LDL continues to accumulate and more 
foam cells are formed, a fibrous cap forms over the growing plaque that may occlude the vessel 
lumen and restrict blood flow [13].  Eventually, sheering stress of blood flow or some other force 
can cause this stable fibrous plaque to rupture and completely restrict blood flow leading to 
potentially fatal heart attack or stroke. 
COMPLEXITY OF ATHEROSCLEROSIS RISK FACTORS 
Atherosclerosis is known to be a complex disease resulting from a combination of risk 
factors, including both environmental and genetic risk factors. Using a forward genetics 
approach, early family studies identified several inherited autosomal dominant forms of 
dyslipidemia, the most common of which is known as familial combined hypercholesterolemia, 
which resulted in abnormally high serum cholesterol levels and an associated increased risk of 
atherosclerosis developing at an early age in affected families [14, 15]. Subsequent large family 
studies were performed to identify the genetic regulators of hyperlipidemia in relation to CVD 
and these lead to the successful identification of several genes regulating plasma cholesterol and 
triglycerides, including CETP, LPL, and LDLR [16, 17]. Subsequent experimental analyses 
implicated dysregulation of lipid levels as having a major influence on the progression of 
atherosclerosis [18]. Taken together, dyslipidemia has been shown to contribute to 
atherosclerosis under conditions of elevated LDL and TC and decreased HDL and specific 
guidelines have been proposed to reduce risk of CVD in individuals based on regulating lipid 
levels [19, 20]. However, dyslipidemia does not account for the overall susceptibility to 
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atherosclerosis as reported in both animal models and human studies. Recent evidence has 
implicated a role for inflammatory responses [21-24] and immune function [25] in 
atherosclerosis progression. 
In addition to the identification of genes linked to atherosclerosis susceptibility within 
families and as a result of variation in known lipoprotein metabolism genes, several human 
GWAS studies have been performed to identify novel genetic loci that contribute to disease 
susceptibility [26]. As of 2003, the Human Genome Project mapped millions of common SNPs, 
representing locations in the genome where a single nucleotide differs between individuals and 
occurs with a minor allele frequency of at least 5% [27]. By associating common SNPs inherited 
preferentially with a disease state, researchers can identify genomic regions that are associated 
with an increased risk of disease susceptibility. This information is then used to inform follow up 
studies with an end goal of identifying the underlying genetic variants and biology regulating the 
association. GWAS studies have proven quite successful in identifying large genomic loci that 
contain genes known to contribute to atherosclerosis and dyslipidemia, such as CETP, LDLR, 
LIPC, the APOA5-APOA4-APOC3-APOA1 cluster, APOB [28-31]. By studying genome-wide 
genetic variants, GWAS studies are well suited to generating new hypotheses and the 
identification of novel genes associated with atherosclerosis and its associated risk factors as 
well. However, most of the loci identified in GWAS studies tend to be large, have modest effects 
on the phenotype, and contain hundreds of candidate genes [32]. As such a human GWAS 
studies require extensive validation of findings in order to identify the underlying genes and 
causal variants responsible for the association. The identification of genetic loci and subsequent 
validation of candidate genes is an exciting avenue for the discovery of novel biomarkers of 
atherosclerosis susceptibility.  
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Laboratory mice have long been used to study the genetics of human diseases and several 
mouse models of atherosclerosis have been developed since the domestication of laboratory 
strains in the early 1900s. The first genetic analyses of atherosclerosis in mice involved the use 
of high fat diets, because normal mice fed a regular chow diet do not develop atherosclerotic 
lesions [33]. Similar to the population-specific susceptibility in humans, these early studies 
identified strain variation in susceptibility to lesions across inbred strains of mice [34]. They also 
identified strain variation in serum levels of lipids, lipoproteins, and apolipoproteins and 
documented the correlation of lipid levels with lesion size [33, 35, 36]. Specifically, Bruell et al. 
identified cholesterol levels ranging from 128 mg/ 100mL in C57BL/6J mice to 208 mg/ mL in 
C3H/HeJ mice and recognized that male mice exhibited significantly higher cholesterol levels 
compared to female mice [37]. Further significant strain, sex, and age differences in lipid levels 
have been observed across unrelated inbred strains of mice [38]. 
These early studies of atherosclerosis in mice utilized undefined diets that often resulted 
in an increased mortality rate and increased morbidity, including secondary disease states such as 
fatty liver and gallstones. In 1985, research by Beverly Paigen identified an atherogenic diet with 
lower concentrations of cholesterol and fat than the original Roberts and Thompson diet that was 
capable of producing lesions in mice without an associated increase in mortality [39].  The 
Paigen diet was a defined mixture of Purina breeder chow and the atherogenic Thomas-Hartroft 
diet, such that the total mixture contained 15% fat, produced appreciable lesions within 10-14 
weeks, and did not cause mortality in treated animals. Using this diet, variation in total plasma 
cholesterol and strain susceptibility to atherosclerosis was characterized across the A/J, AKR/J, 
BALB/cJ, C3H/J, C57L/J, C57BL/6J, DBA/2J, SWR/J, NZB/J, and 129/J common inbred 
strains. They found that BALB/cJ, C3H/J, A/J, SWR/J, and NZB/J mice did not exhibit diet-
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induced lesions after 14 weeks; while 129/J, AKR/J, and DBA/2J exhibited lesions after 14 
weeks and C57L/J and C57BL/6J were the most susceptible to lesion formation exhibiting 
lesions as early as 10 weeks on diet [40]. Additionally, although they observed differences in 
cholesterol levels across the mouse strains, they found that total cholesterol levels were not 
correlated with susceptibility to lesions indicating underlying pathological differences in lesion 
formation. Taken together, these results indicate the relevant impact that the choice of inbred 
strains can have on the interpretation of experimental results. 
Considerations of the impact of diet composition on diet-induced models of 
atherosclerosis led to further advances in defining diets for studies of lesions in mice. In 1990, 
the Paigen group defined the composition of low and high fat purified, synthetic diets [41]. Such 
synthetic diets control for the variable components of chow and reduce the potential influence 
that variable components of standard chow may have on experimental results. By testing 
different sources of fat and cholesterol, a high fat synthetic diet containing 50% sucrose, 15% 
cocoa butter, 1% cholesterol, and 0.5% sodium cholate was optimized to produce aortic lesions 
while reducing the additional pathological burdens of increased ALT, fatty liver, and gallstones 
[41]. 
While early studies of diet-induced lesions in mice were quite successful at identifying 
strain variation in susceptibility to lesions, it was not until the advent of mouse gene targeting 
technologies that the complexity of the development and progression of atherosclerosis could be 
fully elucidated. The generation of the ApoE knockout mouse (ApoE
-/-
) represents the first 
knockout mouse to be characterized as to its effects on atherosclerotic lesions [42]. ApoE is an 
apolipoprotein and a structural component of chylomicrons and IDLs. The presence of ApoE on 
the surface of lipoproteins is recognized by LDLR in the liver, where cholesterol from these 
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particles is deposited. Previous work that led to the creation of the ApoE
-/-
 mouse included 
evidence that a genetic variant in the human ApoE gene, ApoE-2, reduces its ability to bind 
LDLR and results in the early development of atherosclerosis [43, 44].  
Importantly, ApoE
-/-
 mice represent the first mouse model to develop atherosclerotic 
lesions with a similar distribution of severity and appearance of that seen clinically in humans, 
marking a major advance in the ability to characterize mechanisms of atherosclerosis using these 
mice as a model [45]. In the absence of ApoE, mice have significantly increased total cholesterol 
levels (~600 mg/dL) and develop small lesions on a normal chow diet [46, 47]. This phenotype is 
exacerbated by the inclusion of a high fat, high cholesterol “atherogenic” diet containing 15.8% 
fat, 1.25% cholesterol, and 0.5% sodium cholate [48].  
Shortly after the development of the ApoE
-/- 
mouse model, homologous recombination 
was similarly employed to develop a mouse lacking the LDLR known as the Ldlr knockout 
mouse (Ldlr
-/-
) [49]. Mutations in LDLR are recognized as one of the underlying genetic causes 
of familial hypercholesterolemia [50]. The LDL receptor is responsible for recognizing 
circulating lipoprotein particles, particularly ApoB100- and ApoE-containing lipoproteins, and 
deficiencies of LDLR in humans have been shown to cause severe hypercholesterolemia and 
premature atherosclerosis [51, 52]. Ldlr
-/-
 mice have only slightly elevated plasma cholesterol 
levels (~250 mg/dL) on a normal chow diet and develop small lesions comparatively slowly; 
while Ldlr
-/-
 mice fed an high fat diet exhibit extensive atherosclerosis, subcutaneous xanthomas, 
and plasma cholesterol levels equivalent to those seen in the ApoE
-/- 
mice fed an atherogenic diet 
(~1500 mg/dL) [53].  
Extensive use of transgenic and additional knockout mouse models as well as double 
knockout mice have furthered the understanding of the molecular mechanisms of atherosclerosis 
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and the interplay between oxidized LDL deposition within plaques and lipoprotein clearance. 
Construction of ApoE
-/-
; Ldlr
-/-
 double knockout mice allowed researchers to first identify that 
ApoE binds the receptor for chylomicron remnants, LPR, in addition to LDLR [54]. Apobec1
-/-
; 
Ldlr
-/-
 mice were developed and characterized to more accurately reflect the ratio of ApoB100 to 
ApoB48 in humans, since mice express the ApoB mRNA editing enzyme Apobec1 and edit 
ApoB100 to ApoB48 in both the liver and the intestines, while the ApoB48 isoform is limited to 
the intestines in humans [55]. Both Apobec1
-/-
; Ldlr
-/-
 mice and transgenic Ldlr
-/-
 mice 
overexpressing human ApoB100 exhibit severe hyperlipidemia, elevated LDL cholesterol, and 
the development of spontaneous lesions much more severe than the lesions observed in Ldlr
-/-
 
mice alone, which is contributed to the elevated levels of atherogenic ApoB100 particles in these 
mice [56, 57]. These genetic models of atherosclerosis along with diet-induced manipulations of 
the phenotype have made mice a valuable model for studying the genes and pathways regulating 
atherosclerosis. 
As a complement to the reverse genetics approach of knocking out a specific gene and 
measuring altered phenotypes to determine the processes the gene is involved in, a commonly 
used forward genetics approach is to associate naturally occurring alleles with the phenotype of 
interest to pinpoint genetic loci by mapping the phenotypic traits relative to chromosomal 
markers. The chromosomal loci identified can then be thoroughly investigated to determine the 
causal gene and/or variant that is responsible for the measured phenotype [58]. These methods 
have been successfully employed in the identification of genes regulating rare, Mendelian 
disorders. However, many common human diseases are polygenic in nature. Additionally, 
complex diseases such as atherosclerosis, diabetes, and obesity exhibit quantitative variation [59, 
60]. In the case of quantitative traits, the phenotype is continuous and not regulated by a single 
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gene or chromosomal region. In mapping quantitative trait loci (QTLs), the goal is to identify the 
regions of the genome that affect variation in a quantitative trait, such as aortic lesion size or 
serum lipid levels. QTL results are often represented by a LOD score, or logarithm of odds ratio, 
representing the probability of an effect at the locus versus no effect at the locus.  
QTL mapping provides an unbiased approach to identify novel genes influencing 
quantitative traits. Similar to the variation observed in SNPs throughout the human genome and 
across populations, mice exhibit SNPs at which sequence variation occurs across common inbred 
strains. Using available genotype data for SNPs, researchers have performed genome-wide 
linkage studies to identify QTL associated with a multitude of cardiometabolic phenotypes, 
including diabetes, obesity, metabolic syndrome, and atherosclerosis. With the recent advances 
in whole genome sequencing, including the development of high density genotyping arrays, 
genome-wide association studies in mice have contributed to the number of QTLs identified as 
regulating atherosclerosis and its related phenotypes [61]. 
Identification of atherosclerosis QTL across inbred strains takes advantage of several 
crossing strategies including backcross, F2 intercross, or the generation of RILs. The goal of 
each of these crossing schemes is to introduce variation in the phenotype with knowledge of the 
pedigree so that defined chromosomal regions can be identified as QTL influencing the trait. 
Based on the earlier studies that characterized strains as susceptible or resistant to diet-induced 
atherosclerotic lesion formation, researchers were able to design experiments such that variation 
in the trait was introduced by outcrossing animals from susceptible strains to animals from 
resistant strains. A parental cross of an atherosclerosis-susceptible inbred mouse with an 
atherosclerosis-resistant inbred mouse results in the generation of heterozygous F1 animals that 
exhibit an intermediate phenotype. In a backcross, the F1 can then be crossed back to a mouse of 
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one parental genotype to generate an F2 that exhibit recombinations along one chromosome with 
the other chromosome contributed exclusively by the backcross parent such that the F2 will be 
approximately 50% homozygous and 50% heterozygous across the genome. In an intercross, the 
F1 animals are crossed to one another such that chromosomal rearrangements result in 
recombinations between alleles across the genome. In this way, each F2 animal represents a 
unique combination of alleles derived from the two parental strains. QTL can be identified in F2 
mice susceptible to lesion formation that share chromosomal intervals contributed by the 
atherosclerosis susceptible parental strain that are not shared by the F2 animals exhibiting 
resistance to lesion formation.  
QTL mapping studies in inbred mice have identified more than 30 loci regulating 
atherosclerosis. The earliest QTL mapping of atherosclerosis was performed using RILs derived 
from crosses of atherosclerosis susceptible C57BL/6 mice and either BALB/c mice or C3H/He 
mice, both of which are resistant to the development of atherosclerotic lesions [62]. RILs 
represent a stable collection of inbred strains originally derived from carefully selected parental 
strains that are divergent for the phenotype of interest and bred to isogenicity [63]. Using 17 
RILs phenotyped as susceptible or resistant to lesion formation determined by mean number of 
lesions, researchers identified the Ath-1 locus on chromosome 1 [62]. The same group went on to 
identify another locus in RILs derived from C57BL/6J and A/J reciprocal crosses that interacts 
with Ath-1 such that resistant alleles at either locus conferred a resistant phenotype to the animal 
[64]. RIL lines were later used to confirm the identification of Ath-1 and the additional 
identification of Ath-3 [65, 66]. The identification of the Artles locus is an example of an F2 
intercross to identify atherosclerosis QTL. The locus was identified in an F2 cross between 
atherosclerosis-susceptible C57BL/6J mice and atherosclerosis-resistant CAST/EiJ mice [67]. 
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Numerous additional studies have identified QTL regulating atherosclerosis using F2 crosses, 
including 7 crosses of different inbred mouse strains, 5 crosses of ApoE
-/-
 sensitized inbred mice, 
and 2 crosses of Ldlr
-/-
 sensitized inbred mice, the results of which have been summarized in 
recent reviews [68, 69]. Importantly, 63% of atherosclerosis QTLs reported in humans have also 
been identified in homologous chromosomal regions in the mouse, demonstrating the importance 
of QTL mapping in mice for furthering our understanding of the biology underlying this 
detrimental human disease [69]. Ultimately, the goal is to identify the genes at each locus that are 
involved in atherosclerosis and validate their roles in follow up studies in which candidate genes 
are tested independently for a functional role related to the phenotype.   
DISCOVERY OF TMAO AS A RISK FACTOR FOR ATHEROSCLEROSIS  
Even more recently, major roles for the microbiome in human diseases have been 
discovered. Several papers published in the last two years have indicated that intestinal 
microbiota metabolism has an impact on cardiovascular disease risk and the development of 
atherosclerosis [70]. TMAO was identified as a predictive biomarker linking the microbiome and 
CVD risk. TMAO is an oxidation product of trimethylamine (TMA) and it is found in both 
humans and mice.  TMAO is synthesized as a conversion product from TMA, which is derived 
from the breakdown of dietary phosphatidylcholine and is characterized by a strong, fishy odor. 
Classically, studies since the 1970s have indicated an accumulation of gut flora-derived TMA in 
the occurrence of trimethylaminurea (TMAU), which is a genetic disorder characterized by a 
pungent foul body odor and caused by rare mutations in the flavin mono-oxygenase 3 (Fmo3) 
gene [71]. Normally, TMA is oxidized to TMAO primarily through the action of FMO3. TMAO 
was implicated as a potentially proatherogenic metabolite in humans based on a study of human 
patients with clinical manifestations of cardiovascular disease. Recent studies have shown a 
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direct link between plasma levels of TMAO, Fmo3, and atherosclerosis. Several recent studies 
have linked dietary intake of choline, phosphatidylcholine, and L-carnitine with increased 
plasma TMAO levels and increased cardiovascular risk in human subjects [70].  
A study by Hazen et al. showed that hepatic Fmo3 expression and circulating TMAO 
levels were correlated and that variation in TMAO levels could account for 11% of the variation 
in atherosclerotic lesion size among a panel of recombinant inbred strains of mice [72]. 
However, the same study found that treatment of mice with an Fmo3-specific antisense 
oligonucleotide resulted in a 90% reduction in liver Fmo3 mRNA and a corresponding 47% 
decline in plasma TMAO levels, suggesting that, while FMO3 plays a major role in regulating 
TMAO levels, there may be other factors regulating TMAO. Hazen and colleagues then showed 
that TMAO promotes atherosclerosis in C57BL/6J ApoE
-/-
 mice fed a diet supplemented with 
either choline or TMAO and that plasma TMAO is significantly positively correlated with 
atherosclerotic lesion size. They showed that when TMAO is added to the diet of atherosclerosis-
susceptible C57BL/6J ApoE
-/-
 mice, levels of the atherosclerosis-associated inflammatory 
markers CD36 and SR-A1 were significantly increased on macrophages compared to C57BL/6J 
ApoE
-/-
 mice on a chow diet alone. However, while studies using inbred mouse strains have 
shown that TMAO increases atherosclerotic lesion size, surface expression of CD36 and SR-A1, 
and macrophage foam cell formation, it is still unclear what role TMAO plays in promoting 
atherosclerosis. Further analysis of additional regulators of TMAO and studies of the 
contribution of TMAO to atherosclerosis susceptibility in additional mouse populations will be a 
valuable step toward understanding its role in atherosclerosis. Table 1.1 summarizes QTL 
studies performed to identify loci regulating TMAO to date. 
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Table 1.1: Summary of known QTL regulating TMAO levels in mice and humans. 
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DERIVATION OF ADVANCED POPULATION FOR QTL MAPPING IN MICE    
QTL mapping studies in mice have proven quite successful at identifying loci associated 
with atherosclerosis, with at least 30 atherosclerosis loci identified to date [68]. However, many 
of these loci are large and encompass several hundred positional candidate genes that require 
follow up validation to determine the causal associations with the phenotype. Indeed, of the 
known atherosclerosis QTL in mice, only two of the genes underlying them have been identified.  
The gene underlying Ath-1 has been identified as Tnfsf4 in studies using mice with 
targeted mutations in the Tnfsf4 gene which exhibit smaller lesions than control mice [73]. The 
Tnfsf4 gene encodes the OX40 ligand. It is expressed on activated T-cells and promotes survival 
of T-cells at sites of inflammation and could potential exacerbate atherosclerosis via 
proinflammatory mechanisms, although the precise mechanisms by which Tnfsf4 influences 
atherosclerosis are not fully understood [74, 75].   
For the Artles QTL on Chromosome 6, originally identified in an F2 cross between 
atherosclerosis-susceptible C57BL/6J mice and atherosclerosis-resistant CAST/EiJ mice, 
researchers created a congenic strain (CON6) containing the resistant chromosome 6 region from 
CAST/EiJ on an otherwise C57BL/6J genetic background and found that this strain exhibited a 
significant reduction in 5-LO mRNA and protein levels and went on to show that transplantation 
of bone marrow from 5-LO
-/-
 mice to LDLr
-/-
 mice markedly reduced atherosclerotic lesion 
development [76]. 5-LO is a macrophage-expressed enzyme involved in leukotriene biosynthesis 
that is thought to be involved in atherosclerosis via proinflammatory mechanisms [77]. This 
same group undertook the extensive process of creating subcongenic strains to further investigate 
the QTL region and found that there were at least two subregions, termed Ath37 and Ath38, 
which affected the size of atherosclerotic lesions independently of 5-LO [78]. This example is 
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one of many that illustrate the potential complexity of interpreting results of QTL mapping 
studies in inbred strains of mice.  
In an effort to improve the resolution of mapping genetic loci responsible for phenotypic 
variation in mouse models, researchers have begun to use alternative strategies to create more 
genetically heterogeneous populations of mice to perform mapping studies. In 2002, a population 
of heterogeneous stock (HS) mice were first described [79]. The HS mice were derived from 8 
inbred founder strains (A/J, AKR/J, BALBc/J, CBA/J, C3H/HeJ, C57BL/6 J, DBA/2 J, and LP/J) 
and were well suited for fine mapping of QTLs with moderately small effects on the phenotype 
of interest [80]. Indeed, these mice have been used to map 843 QTLs relating to 97 different 
traits, including a chromosome 14 QTL associated with blood glucose and a chromosome 1 QTL 
associated with HDL cholesterol [81]. 
The hybrid mouse diversity panel (HDMP) is a panel of classical inbred strains and 
recombinant inbred strains that, when used for genome-wide association mapping of complex 
traits in mice, has been documented to improve mapping resolution [82, 83]. Several studies 
have utilized HMDP to identify loci of ~1-2 Mb in size [84-91]. Relevant to the study of 
atherosclerosis, Bennett et al. conducted a pivotal study in which they crossed HDMP mice to 
human apoB-100 transgenic mice fed a HFCA diet to induce lesion formation enabling them to 
detect the previously identified Ath30 locus on Chromosome 1 and refine the region to 1.7Mb 
containing 1 mRNA and 31 protein-coding genes. Corroboration of mRNA expression data from 
HMDP and ApoE
-/-
 mice enabled them to identify a single gene, Desmin, as the candidate 
responsible for the atherosclerosis-associated phenotype [92]. Additionally, the previously 
mentioned genome-wide association study for plasma TMAO levels in mice utilized the HDMP 
to identified a chromosome 3 locus encompassing the positional candidate Slc30a7 [93]. 
15 
 
In 2004, a groundbreaking project to develop a population of recombinant inbred lines 
constructed from a mosaic of 5 common inbred strains and 3 wild-derived strains was undertaken 
to advance QTL analysis in mice [94]. The project known as the Collaborative Cross (CC) 
involved the construction of RILs using a unique funnel crossing strategy of the 8 parental 
strains of mice, which included A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, 
CAST/EiJ, PWK/PhJ, and WSB/EiJ. The CC has been proven to be a highly informative 
population for genome-wide analysis due to the increased genetic diversity achieved by the 
inclusion of wild-derived strains and the uniform distribution of this variation [95, 96]. To date, 
the CC contains 12 distributable lines (bred to between 90- 97% homozygosity) and 36 
completed lines (bred to 98% homozygosity) available for genetic analyses. 
QTL MAPPING IN THE DIVERSITY OUTBRED MICE 
The diversity outbred (DO) mice are a population of mice derived from the same eight 
founder strains used to construct the CC mice [97]. The DO mice were designed to maximize 
heterozygosity for improved mapping resolution in QTL analyses. Alleles present in the DO 
mice represent ~90% of the known variation present in laboratory mice due to the inclusion of 
the wild-derived WSB/EiJ, PWK/PhJ, and CAST/EiJ strains and this variation is distributed 
throughout the genomes of DO animals. The DO mice are a population of mice that have been 
strategically outbred to increase the number of recombination events per animal which should 
allow for finer QTL mapping resolution to smaller chromosomal intervals. While the CC RILs 
are maintained as inbred lines, the DO mice are consistently maintained as unique individuals 
outbred randomly every generation for 3 or 4 generations per year. In this way, the population is 
maintained as ~175 genetically diverse lines by random mating of one male and one female from 
the first litter of each previous mating pair. The DO mice represent the same set of allelic 
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variants found in the CC resource, but each DO individual represents a set of uniquely 
segregating alleles. While individual DO animals are genetically unique and cannot be 
replicated, the QTL can effectively be reproduced on different genetic backgrounds with the 
incorporation of follow up studies using the CC mouse resource. As recently reported, the 
contribution from each of the 8 founder strains ranges from 11.3-13.8% and these mice have 
levels of heterozygosity closer to that seen in human populations than traditional laboratory 
mouse strains.  Indeed, the most recent generation of DO mice are estimated to have 
approximately 390 recombination events per animal [98]. Taken together, the DO mice represent 
a valuable resource for the potential of improving QTL mapping resolution to smaller genetic 
intervals encompassing fewer genes for follow up validation studies. 
  Preliminary studies have confirmed that this genetically heterogeneous population has 
the power to improve mapping resolution of complex traits. As of 2012 this population had been 
described and a preliminary analysis of plasma lipid parameters had been reported [97, 98]. 
Specifically, a significant QTL was reported for the variable secondary phenotype change in total 
plasma cholesterol from 8 to 19 weeks in 91 DO mice. A 2-LOD support interval defined the 
QTL as a 2 Mb region containing only 11 genes [98]. Several papers have reported QTL in DO 
mice, including QTL for plasma cholesterol, behavioral phenotypes, and pain sensitivity [99, 
100]. Table 1.2 summarizes the results of the QTL mapping studies conducted to date using DO 
mice. The recent release of the DOQTL mapping software as a freely available R package should 
enable many more researchers to take advantage of the improved mapping resolution the DO has 
to offer [101].  
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Table 1.2: Summary of QTL mapped in DO mice to date [102, 103].  
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SUMMARY OF RESEARCH PRESENTED IN THIS DISSERTATION 
Atherosclerosis is clearly a complex disease and there is still a large gap in our 
understanding of how the disease is regulated. Many advances in our understanding of the 
complexity of this disease have been made over the last few decades and have been outlined in 
this introduction. Cumulatively, it is well known that atherosclerosis is determined by a 
combination of both environmental and genetic risk factors. Epidemiological studies in humans 
and follow up experiments in laboratory mice have identified several major environmental risk 
factors, including smoking, high blood pressure, sedentary lifestyle, diabetes, obesity, and poor 
nutrition. Studies of familial inherited forms of dyslipidemias have implicated both lipid-
associated and non-lipid-associated genetic factors influencing susceptibility to atherosclerosis. 
Mouse studies of atherosclerosis, both diet-induced and gene-targeted approaches, have revealed 
strain-specific influences on the development of atherosclerotic lesions, also indicating a major 
role for genetic variation in influencing this complex trait.  
To date, over 30 atherosclerosis QTL have been identified in mice and the identification 
of novel QTL and the genes underlying the associations is likely to be expedited with the use of 
modern advanced mouse mapping populations. In this study, we performed QTL mapping using 
used the heterogeneous multi-parent DO mouse resource, which contains 37.8 million SNPs and 
6.9 million insertions, deletions, and structural variants that are uniformly distributed throughout 
the genome. The DO mice are designed to be highly informative for QTL mapping due to the 
introduction of allelic variants from multiple founder strains and the accumulation of meiotic 
recombination events resulting in small haplotype blocks that provide high mapping resolution. 
Each DO animal is a mosaic of the eight founder strains used to create the DO mice. We identify 
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here several QTL associated with atherosclerosis and related traits in this cohort of DO mice. 
SIGNIFICANCE OF FINDINGS PRESENTED 
In Chapter 2, we present the first study to date to characterize atherosclerosis in the DO 
mice. We found that DO mice fed a HFCA diet are moderately susceptible to diet-induced 
lesions and that these mice exhibit a large amount of variation in both lesion size and number of 
lesions. We were able to identify a highly significant QTL on Chromosome 6 associated with 
variation in lesion size within the region of the previously identified Ath37 locus. The QTL we 
identified was less than 1 Mb and contained only 6 genes, none of which were previously 
implicated as causal genes underlying the Ath37 locus. We observed that alleles within the locus 
contributed by the founder strain A/J are specifically associated with larger lesion size.  
Based on recent reports, an A/J-specific isoform of Apobec1 has been identified that 
exhibits differential editing efficiency of Apobec1 targets. Our results suggest that this A/J-
specific isoform of Apobec1 could regulate lesion size through editing of target mRNAs, with 
ApoB as the most likely functional target. These findings indicate that the DO mice present a 
valuable resource for studying the complex genetic architecture of atherosclerosis and provide a 
foundation for the use of DO mice in subsequent studies of atherosclerosis and cardiovascular 
disease risk factors.  
In Chapter 3, we investigate genetic regulation of the atherosclerosis-associated metabolite 
TMAO in the DO mice. Prior to this study, it was known that hepatic FMO3 oxidizes TMA to 
TMAO and modulation of Fmo3 expression in the liver can alter TMAO levels. Additionally, 
one mouse study identified a QTL on Chromosome 1 in HDMP mice as contributing to variation 
in TMAO levels across the ~100 inbred strains and RILs used to construct the HDMP, but 
otherwise, very little is known about the role of host genetics in the regulation of TMAO.  
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The study we present here represents the first to characterize genetic regulators of TMAO 
levels in the DO mice. We identified a QTL on Chromosome 12 and a QTL on Chromosome 14 
as associated with TMAO in the DO mice. While the allele effects we observed underlying the 
Chromosome 14 QTL indicated there may be multiple alleles regulating variation in TMAO 
levels at that locus, the Chromosome 12 QTL clearly indicated that contribution of alleles from 
the CAST/EiJ and PWK/PhJ strains at the locus were associated with lower TMAO levels. Based 
on these founder allele effects, we were able to identify one gene, Numb, that exhibits expression 
matching this strain distribution pattern. We measured mRNA expression of Numb in the DO 
mice and identified a highly significant cis-eQTL. Follow up studies are needed to determine 
whether there is a causal relationship between Numb and TMAO.  
Considering the accumulation of evidence that TMAO levels are predictive of CVD risk, 
the identification of genetic regulators of TMAO will be important to understand the biological 
basis of these associations. Although the mechanism has yet to be elucidated, we hypothesize 
that the candidate gene Numb may be regulating TMAO and may represent a novel pathway by 
which the atherosclerosis-associated metabolite is being regulated by host genetics. While Numb 
has not yet been functionally linked to atherosclerosis, we believe that this may represent a new 
pathway to the development and progression of atherosclerotic lesions.  
In Chapter 4, we highlight additional findings of QTL associated with other metabolic 
measures in the DO mice. Specifically, we describe a novel locus on Chromosome 1 that we 
have identified as associated with BUN levels which we were able to resolve at the SNP level. 
We identified a single intronic SNP in Esrrg that matches the founder allele effects at this locus. 
These results and the known biological role of Esrrg in kidney development suggest that this 
gene is likely to be the gene contributing to variation in BUN levels. The identification of such a 
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refined interval associated with this phenotype demonstrates the power of the DO mice to 
expedite candidate gene identification and the determination of the functional significance 
between Esrrg and BUN levels warrants further study.  
Among our significant results, we also identified a Chromosome 8 QTL associated with 
HOMA-IR after dietary treatment that contains 42 positional candidate genes including Fgfr1 
which we identify as a high priority candidate gene based on its known biological function in the 
maintenance of glucose homeostasis. We report an additional 21 QTL that reached suggestive 
significance. Phenotyping additional DO mice for traits exhibiting such suggestive QTL that are 
trending toward genome-wide significance is one approach to assess the validity of suggestive 
QTL prior to conducting follow up studies.  
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CHAPTER 2
1
: HIGH-RESOLUTION GENETIC MAPPING IN THE DIVERSITY 
OUTBRED MOUSE POPULATION IDENTIFIES APOBEC1 AS A CANDIDATE GENE 
FOR ATHEROSCLEROSIS 
 
CHAPTER OVERVIEW 
Inbred mice exhibit strain-specific variation in susceptibility to atherosclerosis and 
dyslipidemia which renders them useful in dissecting the genetic architecture of these complex 
diseases. Traditional quantitative trait locus (QTL) mapping studies using inbred strains often 
identify large genomic regions, containing many genes, due to limited recombination and/or 
sample size. This hampers candidate gene identification and translation of these results into 
possible risk factors and therapeutic targets. An alternative approach is the use of multi-parental 
outbred lines for genetic mapping, such as the Diversity Outbred (DO) mouse panel, which can 
be more informative than traditional two-parent crosses and can aid in the identification of causal 
genes and variants associated with QTL. 
We fed 292 female DO mice either a high-fat, cholesterol-containing (HFCA) diet, to 
induce atherosclerosis, or a low-fat, high-protein diet for 18 weeks and measured plasma lipid 
levels before and after diet treatment. We measured markers of atherosclerosis in the mice fed 
the HFCA diet. The mice were genotyped on a high density SNP array and founder haplotypes 
were reconstructed using a hidden Markov model. The reconstructed haplotypes were then used 
to perform linkage mapping of atherosclerotic lesion size as well as plasma total cholesterol, 
                                                          
1
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triglycerides, insulin, and glucose. Among our highly significant QTL we detected a ~100 kb 
QTL interval for atherosclerosis on Chromosome 6, as well as a 1.4 Mb QTL interval on 
Chromosome 9 for triglyceride levels at baseline and a coincident 22.2 Mb QTL interval on 
Chromosome 9 for total cholesterol after dietary treatment. One candidate gene within the 
Chromosome 6 peak region associated with atherosclerosis is Apobec1, the apolipoprotein B 
(ApoB) mRNA editing enzyme, which plays a role in the regulation of ApoB, a critical 
component of LDL, by editing ApoB mRNA. This study demonstrates the value of the DO 
population to improve mapping resolution and to aid in the identification of potential therapeutic 
targets for cardiovascular disease. Using a DO mouse population fed a HFCA diet we were able 
to identify an A/J-specific isoform of Apobec1 that contributes to atherosclerosis. 
INTRODUCTION 
Identifying novel gene(s) and pathways that regulate susceptibility to atherosclerosis and 
its underlying risk factors is critically important for biomedical science. Genome-wide 
association studies (GWAS) have aided in the identification of more than 50 genomic loci 
associated with atherosclerosis [104] and plasma lipid levels [105, 106]. However, elucidation of 
the mechanisms underlying novel loci resulting from GWAS studies is challenging and in most 
cases such loci only explain a fraction of the genetic variance related to the trait [107-109]. For 
example, GWAS have been successfully used to identify more than 40 loci for coronary artery 
disease (CAD), but these loci in aggregate explain less than 10% of the phenotypic variance 
associated with CAD [110].  
Mouse models are well suited for studies of complex traits such as atherosclerosis 
because environmental conditions and other confounding co-factors can be carefully controlled. 
This reduces the effects of environmental variation on clinical traits and thus increases the 
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portion of the variance that can be explained by genetics. Recently, a “Multiparent Advanced 
Generation Inter-Cross” (MAGIC) population was developed from 8 inbred strains of mice and 
is referred to as the Diversity Outbred (DO) mouse population [97]. The DO mice are mosaics of 
C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ and 129S1/SvImJ and 
these mice complement another large endeavor called the Collaborative Cross (CC) [111]. Both 
the DO and CC populations have tremendous genetic diversity, containing approximately 45 
million segregating SNPs [112]. The DO population is maintained by a randomized outbreeding 
strategy and thus is an ideal resource for high-resolution genetic mapping due to the high allelic 
diversity and increased number of recombinations represented by this population as compared to 
typical inbred mouse strains [98].  
In the current study, we utilize DO mice to study plasma lipids and atherosclerosis. We 
identify a significant QTL for atherosclerosis with a sub-megabase resolution within a locus 
previously identified as associated with atherosclerosis in mice. Using publically available 
expression data and eQTL analysis, we identify Apobec1 as a high probability candidate gene. 
We confirm the eQTL for Apobec1 in the current study using quantitate real time PCR and 
quantitate possible co-regulation of circulating apolipoprotein B (ApoB) protein levels at this 
locus. 
MATERIALS AND METHODS 
Animals and Diets 
Female Diversity Outbred mice (n = 292; J:DO, JAX stock number 009376) were 
obtained from the Jackson Laboratory (Bar Harbor, ME) as 146 full sibling pairs at 4 weeks of 
age and at outbreeding generation 11 (G11) (received September, 2012). The mice were group 
housed (n = 5 mice per cage) with non-irradiated pine bedding and provided with HEPA-filtered 
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air and free access to sterile water in a climate-controlled facility under a 12 hour light:dark 
cycle. Mice were maintained on a defined synthetic diet, AIN-76A, until 6 weeks of age to 
control for differences due to variable components of standard chow (D10001, Research Diets, 
New Brunswick, NJ); subsequently, 146 mice were transferred to a synthetic high-fat, cholic acid 
(HFCA) diet, containing 20% fat, 1.25% cholesterol, and 0.5% cholic acid, to induce 
atherosclerotic lesions and 146 mice were maintained on a high protein diet containing 5% fat 
and 20.3% protein which is not atherogenic (D12109C and D12083101, respectively, Research 
Diets, New Brunswick, NJ). One sibling from each of the 146 sibling pairs was randomly 
assigned to each one of the diets, Figure 2.1. The composition of all diets is listed in Table 2.1. 
The source of fat from the diets varied between the baseline diet (corn oil) fed to the mice from 4 
to 6 weeks of age and the dietary treatment groups (soybean oil plus cocoa butter) fed to the mice 
from 6 to 24 weeks of age. All mice were maintained on their respective diets until 24 weeks of 
age, for a total of 18 weeks. All procedures were approved by the IACUC at UNC Chapel Hill 
(IACUC Protocol Number 11-299). 
Plasma clinical chemistries 
In order to ensure that there were no spurious effects due to the potential variable 
composition of standard laboratory chow, these mice were maintained on a defined synthetic diet 
for 2 weeks (from 4-6 weeks of age). At 6 weeks of age, the mice were anesthetized using 
isoflurane and blood was collected after 4 hours of fasting into EDTA-containing microtubes 
from the retro-orbital sinus. This was repeated at 24 weeks of age, after 18 weeks of dietary 
treatment. Blood samples were centrifuged for 10 minutes at 10000 rpm at 4°C and stored at -
80°C. The plasma levels of total cholesterol, glucose, and triglycerides were quantitated using a 
Biolis 24i Analyzer (Carolina Liquid Chemistries, Winston-Salem, NC). Insulin was determined 
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using the Alpco Mouse Ultrasensitive Insulin ELISA assay (Alpco  Inc, Salem, NH); samples 
and controls were run in duplicate and optical densities were measured at 450 nm using a 
microplate reader and analyzed with Gen5 Data Analysis Software (Bio-Tek, Winooski, VT). 
Data are presented as mean + SD and significance was determined using a Student’s t-test. 
Atherosclerotic lesion size 
Hearts, including the proximal aorta, were carefully dissected from 24-week-old mice, 
perfused with 1X PBS, and stored in 10% formalin at 4˚C. A transverse cut, parallel to the atria, 
was made to remove the top portion of the hearts which were then embedded in Optimal Cutting 
Temperature compound (O.C.T.) and stored at -80˚C. Serial sections (10 µm thick) from the 
aortic sinus were mounted onto slides. Cross sections were arranged 8 to a slide and 
approximately 10-14 total slides were obtained from each mouse heart, for a total of 80-104 
cross sections through 400-560 µm of the aortic sinus per animal. Sections were stained with Oil 
Red O to measure lipid accumulation. Briefly, slides were fixed with formalin for 15 minutes, 
rinsed with water then 60% isopropanol, stained for 1 hour in freshly prepared Oil Red O 
solution, and rinsed with 60% isopropanol then water. Once stained, the slides were imaged 
using a Zeiss AxioCam MR3 (Zeiss, Munich, Germany) and atherosclerotic lesion area was 
quantified using Image J software (http://imagej.nih.gov/ij). Data are presented as the average 
lesion area in µm
2
.   
Apobec1 mRNA isoform expression 
QPCR was performed in triplicate using a High Capacity Reverse Transcriptase Kit 
(Applied Biosystems, Foster City, CA). Following cDNA conversion, 1 µL of sample cDNA, 2 
µL KAPA Sybr Fast qPCR mastermix (KK4610), and 0.5 µM primers was added to each well of 
a 384-well plate. Apobec1 primers were custom designed and ordered from Eurofins MWG 
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Operon (Huntsville, AL). The long transcript was amplified using the following primer set 5’-
cagcggtgtgactatccaga-3’ (left primer) and 5’-ttggccaataagcttcgttt-3’ (right primer). This primer 
set was designed to recognize the known Apobec1 transcript Apobec1-001 
(ENSMUST00000112586.1). The short transcript was amplified using the following primer set 
5’-cccatgagcgttggattc-3’ (left primer) and 5’-tcaaccacgggcagtctt-3’ (right primer). This primer 
set was designed to recognize the known Apobec1 transcript Apobec1-004 
(ENSMUST00000143356.1). A serial dilution of pooled samples was used to create a standard 
curve. Sterile water was used as a negative control.      
Quantification of ApoB in the DO mice 
 Total ApoB protein levels were measured using the mouse Apolipoprotein B Sandwich-
ELISA method in 96-well format using the ApoB ELISA kit from Elabscience (Wuhan, China) 
in duplicate following the manufacturer’s instructions. Optical densities were measured at 450 
nm using a microplate reader and analyzed with Gen5 Data Analysis Software (Bio-Tek, 
Winooski, VT). 
Differential expression of genes in peak regions 
Data were obtained from The Jackson Laboratory Gene Expression Strain Survey and 
used for the analysis of differential expression of candidate genes from liver tissue of female  
C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ and 129S1/SvImJ 
mice (http://cgd.jax.org/gem/strainsurvey26/v1). Mice were maintained for 11 weeks on standard 
chow diet (4% fat content). Genes were identified as differentially expressed between the DO 
founder strains using analysis of variance and significant between strains differences were 
calculated using Tukey’s Post Hoc test. We used a Bonferroni correction to determine statistical 
significance and correct for multiple comparisons. 
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Genotyping  
DNA was extracted and purified from tail biopsies taken from 6-week-old mice using 
Qiagen DNeasy kit according to the manufacturer’s instructions. Genotyping was performed 
using the Mega Mouse Universal Genotyping Array (MegaMUGA) by GeneSeek (Neogen, 
Lansing, MI) [113]. The call rate exclusion criteria was set at >95% and twelve mice were 
excluded based on this criteria; the average call rate of the genotyped mice used in the study was 
98%. The MegaMUGA array is built on the Illumina Infinium platform and contains 77,808 SNP 
markers that are distributed throughout the genome at an average spacing of 33 Kb. The 
MegaMUGA SNPs were subset to include 57,977 informative SNPs that distinguish among the 
genotypes of the eight founder strains. For the mapping, genomes were reconstructed based on 
the X and Y allele intensities from the array and founder haplotypes were reconstructed using a 
hidden Markov model. The founder allele dosages based on the reconstructed haplotypes were 
then used to perform linkage mapping. 
QTL Mapping 
QTL mapping was performed using the R package DOQTL version 0.99. Briefly, 
DOQTL reconstructs the genome in terms of founder haplotypes and performs QTL mapping by 
regressing the phenotypes on the founder haplotypes with an adjustment for kinship between the 
mice. Phenotypes were natural log-transformed to satisfy the model assumption of a normal 
distribution. Diet was included as an additive covariate for post diet measurements, except lesion 
size which was performed using only the subset of mice fed the HFCA diet (n=146). Candidate 
genes were identified by position based on the Wellcome Trust Sanger mouse genomes database, 
www.sanger.ac.uk, release 1303 based on genome assembly GRCm38 [114]. QTL support 
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intervals were defined by the 95% Bayesian credible interval, calculated by normalizing the area 
under the QTL curve on a given chromosome [115]. 
The mapping statistic reported is log of the odds ratio (LOD). The significance thresholds 
were determined by performing 1000 permutations of genome-wide scans by shuffling 
phenotypic data in relation to individual genotypes. Significant QTL were determined at a 
genome-wide p-value of < 0.05 and suggestive QTL were determined at a p-value of < 0.63. The 
latter corresponds to one false positive per genome scan [116]. 
RESULTS 
Effects of Diet on Clinical Markers of Cardiovascular Disease in Diversity Outbred Mice 
Our studies using the DO mice were designed to examine nutrigenetic or gene x diet 
interactions and the overall design is outlined in Figure 2.1. Thus, we utilized several diets that 
we outline here. First, in order to standardize our measurements for this study and our planned 
future studies, all of the DO mice were placed on a synthetic, chemically-defined diet (AIN-76) 
upon arrival at the University of North Carolina, Chapel Hill. This diet is henceforth referred to 
as the baseline diet and was administered for 2 weeks. After two weeks of this defined diet, all 
292 DO mice were phenotyped for a variety of clinical traits associated with cardiovascular 
disease risk. These data were used for QTL mapping. At the end of the two week baseline diet, 
one mouse from each sibling pair was assigned to one of two diets for subsequent investigation 
of gene x diet interactions. These diets were also synthetic and chemically defined and included a 
high-fat, cholic acid diet designed to induce atherosclerosis and a high protein diet not expected 
to be atherogenic. The DO mice were fed these diets for 18 weeks and then phenotyped at 24 
weeks of age.  
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There was considerable variation among the mice in the clinical traits measured while the 
mice were on the baseline diet, Table 2.2. After diet treatment, there was a robust and 
statistically significant increase in plasma cholesterol in response to the HFCA diet (199.9 ± 68.6 
mg/dl) compared to both the high protein diet (91.7 ± 25.1 mg/dl) and baseline levels (97.6 ±31.5 
mg/dl), Figure 2.2 and Table 2.2. Conversely, triglyceride levels decreased in response to the 
HFCA diet (32.3 ± 12.2 mg/dl) compared to both baseline levels (59.3 ± 26.7 mg/dl, p<0.05) and 
in mice on the high protein diet (57.7 ± 30.8 mg/dl, p<0.05), Figure 2.2 and Table 2.2.  
Identifying QTL for Clinical Markers of Cardiovascular Disease in the DO at baseline 
           We performed QTL mapping for several clinical markers of cardiovascular disease in 6-
week-old mice fed the baseline (AIN-76) diet. Significant QTL were determined at a genome-
wide p-value of <0.05 and the QTL support interval was defined using the 95% Bayesian 
credible interval, Table 2.3. We identified a highly significant QTL for triglycerides on 
Chromosome 9 with a peak SNP located at 51.4 Mb (LOD=11.3; n= 262 mice), Figure 2.3A. 
DO mice carrying the CAST/EiJ allele at the Chromosome 9 QTL have higher triglyceride 
levels, Figure 2.4A. There are 34 candidate genes within the QTL interval on Chromosome 9, 
Figure 2.4B. We identified suggestive QTL for total cholesterol at baseline on Chromosome 13 
with a peak SNP located at 30.4 Mb (LOD=6.5; n= 277 mice), Figure 2.3B, and for glucose at 
baseline on Chromosomes 5 and 7 with peak SNPs located at 92.6 Mb on Chromosome 5 
(LOD=7.0; n= 257 mice) and 27.2 Mb on Chromosome 7 (LOD=6.5; n= 257 mice), Figure 
2.3C.   
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Identifying QTL for Clinical Markers of Cardiovascular Disease in the DO after dietary 
treatment 
To assess the effects of diet in the DO, we determined the genetic architecture of several 
markers of cardiovascular disease by quantifying these phenotypes at 24 weeks of age after 
dietary treatment. Because diet had significant effects on the phenotypes, it was included in the 
mapping model as an additive covariate. We observed a significant QTL for plasma cholesterol 
on Chromosome 9 with a peak LOD score of 7.54 at 48.3 Mb (47.84 Mb- 70.04 Mb), Figure 
2.5A and Table 2.3. The CAST/EiJ founder haplotype was associated with high levels of 
cholesterol based on the founder allele contribution in the region, Figure 2.5B. This is a 
relatively large QTL interval of 22.2 Mb based on the Bayesian credible interval (p= 0.95) and 
the entire interval contains 391 known and predicted genes. The peak SNP is within 3 Mb of the 
peak SNP identified by mapping of baseline triglyceride levels in this population of mice, 
suggesting that this genes at this locus are critical in the overall regulation of lipid metabolism.  
Differential expression of candidate genes in DO founder strain mice 
In order to prioritize candidate genes within the QTL interval we identified as associated 
with triglycerides, we analyzed hepatic gene expression among the founder strains for the 34 
genes in the region from a publically available dataset (http://cgd.jax.org/gem/strainsurvey26). 
We first identified genes whose expression varies across the progenitor strains using 1-way 
ANOVA analysis and using a Bonferroni correction based on the number of probes tested 
(0.05/68 probes representing the 34 genes in the locus). Based on this analysis, we identified 10 
probes representing 9 genes that are differentially expressed: 1110032A03Rik, 1810046K07Rik, 
Alg9, Bco2, Cryab, Gm684, Ppp2r1b, Pts, and Sik2, Figure 2.6A-I. 
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We can identify the contribution of the founder alleles to the QTL using the founder 
coefficients from the QTL mapping. For the Chromosome 9 triglyceride QTL, we observed that 
allelic contribution from the CAST/EiJ founder at this locus is associated with higher triglyceride 
levels, while comparatively low triglyceride levels are associated with allelic contribution from 
the other seven founder strains, Figure 2.4A. Thus, we next performed pair-wise comparisons 
using Tukey’s HSD for the 9 differentially expressed genes to identify genes which are 
differentially expressed in CAST/EiJ compared to the other founder strains and thus match the 
overall allelic effects at the QTL. Of the 9 genes differentially expressed, Bco2 and Ppp2r1b 
most closely match the allele effects of the QTL and are differentially expressed between 
CAST/EiJ and the other progenitor strains, Figure 2.6A and B. We note that the locus we 
identified is adjacent to a region harboring genes known to influence plasma lipid levels 
including: Apoa1, Apoa4, Apoa5 and Nnmt. Both Apoa4 and Nnmt are differentially expressed 
among the strains, but only Nnmt is differentially expressed in CAST/EiJ mice, Figure 2.7. 
Identification of Apobec1 as a candidate for regulating lesion size in DO mice  
Atherosclerosis is a complex trait and studies using mice have identified numerous QTL 
for this trait [69] but this trait has not yet been evaluated in the DO mice. Based on previous 
studies, a high-fat diet containing cholic acid (HFCA) can induce formation of atherosclerotic 
lesions [62]. Indeed, we found that none of the mice fed the high protein diet exhibited any 
lesions and our subsequent analyses focus only on the subset of DO mice that were fed the 
HFCA diet. 
We found that 76% of the DO mice were susceptible to atherosclerosis with lesions 
induced by the HFCA diet, with a range in lesion size from 38 to 33,200 µm
2
. Based on this 
highly variable phenotype, we were able to identify a highly significant QTL on Chromosome 6 
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(LOD=10.7; 122.6 - 122.7 Mb), Figure 2.8A. Although our Chromosome 6 peak SNP, 
UNC11996440, is within the 95% confidence interval of a previously reported QTL, Ath37, the 
interval is refined to sub-Mb resolution using the DO. The 95% confidence interval reported for 
this previously defined QTL encompasses an 11.8 Mb interval, while our Chromosome 6 
atherosclerosis peak maps to a refined 100 kb region containing 6 genes, Figure 2.8C. One 
candidate gene within the Chromosome 6 peak region is Apobec1, the apolipoprotein B mRNA 
editing enzyme, which plays a role in the regulation of ApoB, a critical component of LDL, by 
editing ApoB mRNA to produce the short ApoB48 isoform.  Misregulation of Apobec1 results in 
altered ApoB isoform editing. For example, Apobec1
-/-
 mice have higher levels of ApoB100 
compared to the edited isoform, ApoB48 [117] and transgenic rescue of Apobec1 in Apobec1
-/-
 
animals has been shown to directly alter chylomicron production [118]. Apobec1 is an attractive 
candidate gene for influencing diet-induced lesion size based on the known function of Apobec1 
in lipid homeostasis and a causal allele for Apobec1 has not been previously identified as 
associated with atherosclerosis. Additionally, we found that total cholesterol levels after dietary 
treatment were significantly correlated with both the short and long isoforms of Apobec1 (r=0.6 
and r=0.57, respectively), but not ApoB levels in these mice (r= 0.06). 
A/J specifically expresses a long isoform of Apobec1 and this is induced in response to a 
high-fat, cholic acid diet 
We found that DO mice containing the A/J allele at the Chromosome 6 QTL had larger 
aortic lesions, Figure 2.8B. Among genes in the Chromosome 6 QTL interval, only Apobec1 has 
significant differential hepatic expression in the A/J strain, which expresses higher levels of 
Apobec1 ( p< 0.0125), Figure 2.8D-G. Interestingly, strain-specific differences in isoform 
expression of Apobec1 were recently identified between A/J and C57BL/6J mice, where 
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C57BL/6J mice express a truncated Apobec1 protein [119]. More importantly, using AXB and 
BXA recombinant inbred strains they demonstrate genetic regulation of mRNA editing by 
Apobec1, such that animals expressing the A/J-specific isoform of Apobec1 exhibit higher 
editing efficiency of Apobec1 targets as compared with C57BL/6J animals.  
We quantitated the expression of Apobec1 in liver tissue from A/J and C57BL/6J mice 
fed either the HFCA diet or the control synthetic diet and found that on the synthetic diet A/J 
expresses more of the long isoform of Apobec1 compared to C57BL/6J, Figure 2.9B, while A/J 
and C57BL/6J express similar levels of the short isoform of Apobec1 while on a synthetic diet, 
Figure 2.9A. In response to the HFCA diet, expression of both isoforms of Apobec1 is 
significantly increased in both A/J and C57BL/6J mice compared to Apobec1 levels in the mice 
on the synthetic diet (p> 0.05). The short isoform of Apobec1 is induced 2.5-fold in C57BL/6J 
animals and 3.5-fold in A/J animals in response to the HFCA diet. The long Apobec1 isoform is 
induced 2.5-fold in C57BL/6J animals and 4-fold in A/J animals.  
Cis-eQTL for Apobec1 exhibit isoform-specific allele effects patterns in the DO mice 
Based on the differences in expression of Apobec1 between A/J and C57BL/6J mice, we 
hypothesized that the expression of Apobec1 may be genetically regulated.  Thus, we surveyed 
two publically available databases for expression QTL data to determine if a natural variant near 
the Apobec1 gene affects its expression. Specifically, we queried a panel of inbred strains of 
mice called the hybrid mouse diversity panel (HMDP) and The Jackson Laboratory’s Diversity 
Outbred eQTL viewer, data located at http://systems.genetics.ucla.edu/data/hmdp and 
http://cgd.jax.org/apps/eqtlviewer-beta/, respectively [83]. Apobec1 expression varied 
significantly among the HMDP strains and the major locus regulating expression mapped 
directly over the Apobec1 gene, at 122 Mb on Chromosome 6 (data not shown). Similarly, the 
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Jackson Laboratory’s DO eQTL viewer identifies a cis-eQTL associated with Apobec1 
expression, Figure 2.10A. Similar to our results, these data demonstrate that the A/J allele is 
associated with higher expression of Apobec1, Supplemental Figure 2.10B.  
Considering our observations of the effect of genetic background on Apobec1 expression 
in liver tissue and recent observations that mouse genetic background regulates isoform usage in 
macrophages, we next asked if there was a difference in the genetic regulation of each of these 
isoforms among the DO founder strains. We performed QTL mapping of mRNA expression 
levels of either the short or long isoform of Apobec1 from RNA isolated from liver tissue from 
the present DO mouse study population. We identified highly significant cis-eQTL for both 
isoforms on Chromosome 6 with the peak SNP located at 121.8 Mb with a maximum LOD score 
of 9.9 associated with expression of the short isoform (p<0.05, n= 252 mice) and at 123.4 Mb 
with a maximum LOD score of 15.7 associated with expression of the long isoform (p<0.05, n= 
251 mice), Figure 2.11A and 2.11B, respectively. When we estimate the effect of each founder 
at each marker along Chromosome 6, we see that CAST/EiJ alleles are associated with higher 
expression of the short isoform, Figure 2.11C, while A/J alleles are associated with higher 
expression of the long isoform, Figure 2.11D. We also mapped the ratio of Apobec1 isoforms 
and observe a highly significant cis-eQTL with a max LOD score of 41.0 at 122.6 Mb (p<0.05, 
n= 251 mice), Figure 2.11E and 2.11F. 
Apobec1 and ApoB levels are dependent on the genotype of UNC11996440, the 
Chromosome 6 peak SNP associated with atherosclerosis. 
Based on the association of the A/J founder with atherosclerotic lesion size, we 
hypothesized that a causal allele located in the Apobec1 sequence would be private to A/J. 
However, there are no documented SNPs that are private to A/J within the refined peak region of 
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122.6-122.7 Mb on Chromosome 6. The peak SNP for this locus, UNC11996440, is located 
distal to the Apobec1 gene on Chromosome 6 at 122.67 Mb, while Apobec1 lies between 122.5-
122.6 Mb.  In addition to the cis-eQTL data for Apobec1 expression, this suggests that a distant 
SNP affecting Apobec1 expression may be responsible for the association between the A/J 
haplotype and atherosclerotic lesion size. However, if the association of the A/J haplotype with 
increased lesion size in the DO mice is mechanistically related to Apobec1 expression, then we 
would expect Apobec1 expression levels to differ based on the genotype of UNC11996440. We 
identified T as the major allele (frequency = 0.69) and C as the minor allele (frequency = 0.31) at 
the tagging SNP UNC11996440. The genotype at this SNP significantly affects Apobec1 mRNA 
expression levels (p >0.001), Figure 2.12A. We next hypothesized that the association at this 
locus may be mechanistically related to the role of Apobec1 in editing its primary target ApoB, 
as elevated plasma ApoB is a known risk factor for atherosclerosis. Therefore, we quantified 
plasma ApoB levels in duplicate using two mouse-specific ApoB Sandwich-ELISA plates (N=80 
mice). Plasma samples from only the high-fat, cholic acid diet-fed mice were used and samples 
were chosen to represent a range of atherosclerotic lesion sizes. As shown in Figure 2.12B, 
ApoB levels are significantly different between the genotype groups at the tagging SNP 
UNC11996440 (p >0.001). Therefore, in addition to identifying the A/J-specific isoform of 
Apobec1 as associated with atherosclerotic lesion size in the DO mice, these data suggest that 
this association may be attributable to the role of Apobec1 in editing ApoB. 
DISCUSSION 
The DO was designed to be a high-resolution genetic mapping panel.  The use of DO 
mice for mapping offers a number of advantages over classical approaches to mouse genetics, 
including high mapping resolution, increased heterozygosity, and uniformly distributed genetic 
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variation across the genome [98]. Using the newly developed DO mouse resource, we were able 
to refine the positions and identify new candidate genes for previously mapped QTL for 
atherosclerosis, a highly complex phenotype associated with human disease.  We further 
interrogate this QTL using publically available data, by quantitating mRNA levels for Apobec1 
and by investigating the protein target of Apobec1 to identify a potential mechanism for this 
QTL. We discuss each of these in detail. 
Atherosclerosis in the DO 
Atherosclerotic lesion development is the most common cause of cardiovascular disease. 
Here, we characterize for the first time the development of diet-induced atherosclerotic lesions in 
the newly developed DO mouse population. In the present study, 292 mice on either a high-fat, 
cholic acid diet designed to induce atherosclerotic lesions or a non-atherogenic, low-fat, high 
protein diet were phenotyped for atherosclerosis. We found that none of the mice fed the high 
protein diet exhibited any lesions. We found that 76% of the DO mice were susceptible to lesions 
induced by the HFCA diet, with a range in lesion size from 38 to 33,200 µm
2
. We detected one 
locus on Chromosome 6 for atherosclerosis that maps within the 95% CI of a previously reported 
QTL, Ath37, [78] which was identified in studies using sub-congenic mice between C57BL/6J 
and CAST/EiJ. The locus in the current study contains Apobec1, which was originally described 
as the enzyme responsible for deamination of a cytosine in mature ApoB mRNA, resulting in a 
premature stop codon and production of the truncated protein ApoB48. Lipoproteins containing 
ApoB48 are more efficiently cleared from the circulation as demonstrated by adenoviral 
overexpression studies that reduce plasma lipid levels [120]; in contrast, Apobec1
-/- 
mice 
synthesize only apoB-100 and have increased atherosclerosis when crossed to Ldlr
-/-
 mice [55].  
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Closer examination of the locus we identified here indicates that A/J mice contain a 
susceptible allele, which is unexpected as A/J has classically been defined as an atherosclerosis-
resistant mouse strain [40]. However, it is possible that if Apobec1 editing is affected by an allele 
carried by the A/J strain, this effect could be masked by transgressive variation or epistasis in 
inbred A/J animals. When we queried the Sanger SNP database for alleles private to A/J within 
10 kb of the Apobec1 gene sequence (122,567,890- 122,612,426 Mb), we found that there are no 
documented SNPs that are private to A/J. However, the association of distant SNPs influencing 
gene expression of genes as far as 300 kb away is not uncommon [121]. While our data suggests 
that a distant SNP affecting Apobec1 expression may be responsible for the association between 
the A/J haplotype and atherosclerotic lesion size, we have not yet ruled out an association 
between lesion size and the other five genes in the locus, nor have we ruled out nearby genes 
with A/J-specific alleles. Additionally, in our study we did not find lesion size to be correlated 
with Apobec1 expression (r = -0.02) although total cholesterol was correlated with this 
phenotype (r = 0.60). 
Recently, Hassan and colleagues have reported that genetic differences between 
C57BL/6J and A/J at the Apobec1 gene affect global RNA editing patterns between these strains 
[119]. Indeed, this study identified an A/J-specific isoform of Apobec1 in murine macrophages 
that increased the editing efficiency of this enzyme for multiple Apobec1 targets [119, 122].  
Thus, differences in Apobec1 structure or expression could affect editing or perhaps overall 
levels of ApoB or another of Apobec1’s target genes. Our initial studies, in a subset of the DO 
mice used in this study, indicate that total ApoB levels may be influenced by this locus.   
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Mapping Clinical Markers of Cardiovascular Disease in the DO 
Measures of cholesterol, triglycerides, and glucose are commonly used markers of 
cardiovascular disease. Therefore, we were interested in investigating the genetic architecture of 
these traits in the DO mice. We identified highly significant QTL for triglycerides in mice at 
baseline.  The significant QTL on Chromosome 9 for baseline triglycerides is 1.4 Mb in size and 
is coincident with a ~30 Mb QTL previously identified as associated with triglyceride levels in 
C57BL/6J x KK-Ay/a F2 mice, Trigq1. Trigq1 maps to 61 Mb on Chromosome 9 with a peak 
LOD score of 4.2 at the marker D9Mit163 [123]. The large Trigq1 locus includes multiple gene 
candidates known to regulate lipid levels such as the ApoA5-ApoA4-ApoA3-ApoA1 gene cluster 
and Lipc. While the ApoA5-ApoA4-ApoC3-ApoA1 gene cluster is located at 46.2 Mb, just 
proximal to the QTL interval we identified here and Lipc is located 20 Mb distal to our peak 
region, these genes would seem to be excluded based on our results. However, at least one of 
these genes, ApoA5, has been well characterized as associated with triglyceride levels [124]. In 
humans, a mutation in ApoA5, also called the Delhi gene, is linked to extremely elevated 
triglyceride levels and increased risk of cardiovascular disease [125, 126]. Hepatic lipase, 
encoded by the Lipc gene, hydrolyzes triglycerides and phospholipids in lipoprotein particles and 
is therefore also likely to be functionally associated with heart disease. We utilized publically 
available gene expression data to prioritize genes whose expression may be genetically 
regulated. These analyses are not able to identify candidate genes that have a functional variant 
that affects protein function, protein stability, or binding. Further study to confirm that one of the 
genes in the triglyceride QTL identified in this study is a causal gene remains to be performed. 
This region of Chromosome 9 clearly contains multiple genes that are important for the 
regulation of cardiovascular disease risk factors. We also identified the same region as associated 
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with total cholesterol after dietary treatment in our DO mouse population. Additionally, the 
human syntenic region of the Chromosome 9 QTL we identified as associated with both baseline 
triglycerides and total cholesterol after dietary treatment has been identified in several human 
GWAS studies as associated with multiple atherosclerosis risk factors across multiple human 
populations [127-129]. When one QTL contains more than one causal variant, the Bayesian 
interval calculation may fail to differentiate genetic signals from the closely linked genes. 
Several studies have suggested the use of 2-LOD support intervals for generating conservative 
estimates of genes for candidate testing. Indeed, in our study the 95% Bayesian credible intervals 
represent approximately 1-LOD support intervals for baseline triglycerides and for total 
cholesterol after diet treatment and if we broaden these intervals to 2-LOD support intervals, the 
ApoA5-ApoA4-ApoA3-ApoA1 gene cluster and Lipc gene falls within the more conservative 
interval estimate. 
We identified a suggestive QTL for total cholesterol on Chromosome 13 with a peak SNP 
located at 30.4 Mb (LOD=6.5; n= 277 mice) and for glucose on Chromosome 5 with a peak SNP 
located at 92.6 Mb (LOD=7.0; n= 257 mice). These suggestive QTL co-localize with previously 
reported QTL. The Chromosome 13 locus associated with baseline cholesterol levels is just 
proximal to Lipq2, which was identified in backcross between MOLF/EiJ and C57BL/6J mice on 
with an Ldlr
-/-
 mutation [130]. The suggestive QTL associated with blood glucose on 
Chromosome 5 is less than 2 Mb from the peak SNP reported for the QTL, Bglu13, which was 
identified in an F2 intercross cross of mutant C3H/HeJ and C57BL/6J carrying the ApoE
-/-
 
mutation [131]. 
In summary, we demonstrate here the use of the Diversity Outbred mice for high 
resolution mapping of traits related to atherosclerosis. We identify several candidate genes for 
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triglycerides in mice on a synthetically defined diet. Perhaps the most interesting result is the 
identification of an atherosclerosis QTL on Chromosome 6 that is 100 kb in size. This locus 
contains the candidate gene Apobec1 which is known to alter circulating lipoprotein 
composition, but also has widespread RNA editing capabilities, perhaps indicating an additional 
mechanism by which susceptibility to atherosclerosis is regulated. 
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Figure 2.1- Overall design of the QTL mapping study. Mice obtained from the Jackson 
Laboratory were fed a chow diet of variable composition prior to arriving at the UNC Mouse 
Facilities at 4 weeks of age. Mice were transferred to a controlled synthetic diet from 4 to 6 
weeks of age (AIN-76A). At 6 weeks of age, clinical markers of cardiovascular disease were 
measured and baseline QTL mapping was performed. The mice were then transferred to one of 
two diet groups such that one sibling of each sib pair was randomly assigned to either the high-
fat, cholic acid diet group designed to induce atherosclerosis or the high protein diet group 
expected to be non-atherogenic. QTL mapping was then performed in 24-week-old mice after 
diet exposure. Quantification of atherosclerotic lesions was performed in the mice at 24 weeks of 
age. 
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Figure 2.2- Effects of Diet on Cardiovascular Risk Factors in Diversity Outbred Mice. Mice 
were maintained on a synthetic diet for two weeks, fasted for four hours, and then phenotyped 
for plasma clinical chemistries at 6 weeks of age (Baseline). Following two weeks of synthetic 
diet, mice were transferred to either a high protein diet (HP) or an atherogenic diet (HFCA). 
Plasma was taken from 24-week-old mice after 18 weeks on their respective diets, and with four 
hours fasting, and then phenotyped for plasma clinical chemistries after diet treatment (Treated).  
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Figure 2.3- QTL mapping of clinical markers of cardiovascular disease in 6-week-old DO 
mice at baseline. Genome-wide QTL scans for loci affecting plasma levels of triglycerides (A.), 
total cholesterol (B.), and glucose (C.) in the DO population at baseline. Chromosomes 1 through 
X are represented numerically on the x-axis and the y-axis represents the LOD score. The relative 
width of the space allotted for each Chromosome reflects the relative length of each 
Chromosome. Mice were maintained on a synthetic diet for 2 weeks and then phenotyped for 
plasma clinical chemistries at 6 weeks of age. Colored lines show permutation-derived 
significance thresholds (N=1000) at P = 0.05 (LOD=7.57, shown in red), P = 0.10 (LOD=7.17, 
shown in orange), and P = 0.63 (LOD=5.79, shown in yellow).  
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Figure 2.4- High-resolution mapping of significant QTL on Chromosome 9 associated with 
plasma triglyceride levels. The eight coefficients of the QTL model show the effect of each 
founder haplotype on the phenotype. The model coefficients for the mapping of baseline 
triglycerides are plotted for each founder allele at each marker along Chromosome 9 and shading 
identifies the 95% Bayesian estimated interval around the peak (A). There are 36 potential 
candidate genes within the Chromosome 9 locus associated with plasma triglycerides at baseline 
(B). 
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Figure 2.5- QTL mapping of total cholesterol after dietary treatment in the DO mice. 
Genome-wide QTL scan for loci affecting plasma levels of total cholesterol after 18 weeks of 
dietary treatment (A). Chromosomes 1 through X are represented numerically on the x-axis and 
the y-axis represents the LOD score. The relative width of the space allotted for each 
chromosome reflects the relative length of each chromosome.  Plasma was taken from 24-week-
old mice after 18 weeks of dietary treatment. Colored lines show permutation-derived 
significance thresholds (N=1000) at P = 0.05 (LOD=7.57, shown in red), P = 0.10 (LOD=7.17,  
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shown in orange), and P = 0.63 (LOD=5.79, shown in yellow).  The eight coefficients of the 
QTL model show the effect of each founder haplotype on the phenotype. Shading identifies the 
95% Bayesian credible interval around the peak (B.).   
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Figure 2.6- Liver expression of candidate genes in the Chromosome 9 peak region 
associated with baseline triglyceride levels. Gene expression data was obtained from livers of 
female C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ and 
129S1/SvImJ mice (http://cgd.jax.org/gem/strainsurvey26). Hepatic gene expression of 68 
probes representing the 34 genes at the locus were compared. Differential expression of genes 
across the founder strains was determined using a 1-way ANOVA analysis and a Bonferroni 
correction for multiple tests. We identified 9 genes as differentially expressed among the founder 
strains: Ppp2r1b, Bco2, Pts, Alg9, Sik2, 1110032A03Rik, Gm684, Cryab, and 1810046K07Rik 
(A.–I.). Bco2 and Ppp2r1b are differentially expressed between CAST/EiJ and the other 
progenitor strains and, therefore, most closely match the allele effects of the QTL.  
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Figure 2.7- Liver expression of genes previously associated with markers of cardiovascular 
disease on Chromosome 9. Gene expression data was obtained from livers of female C57BL6/J, 
A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ and 129S1/SvImJ mice 
(http://cgd.jax.org/gem/strainsurvey26). Hepatic gene expression of Chromosome 9 genes 
previously identified as associated with triglyceride levels were compared. Differential 
expression of genes across the founder strains was determined using a 1-way ANOVA analysis 
and a Bonferroni correction for multiple tests. Apoa1 and Apoa5 were not differentially 
expressed across the founder strains (A. and C.). Apoa4 was differentially expressed among the 
founder strains, but only Nnmt was differentially expressed in CAST/EiJ compared to all of the 
other founder strains (B. and D.). 
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Figure 2.8- QTL mapping of atherosclerosis in the DO mice. Genome-wide QTL scan for loci 
affecting atherosclerotic lesion size in mice fed a high-fat, cholic acid diet (A.). Chromosomes 1 
through X are represented numerically on the x-axis and the y-axis represents the LOD score. 
The relative width of the space allotted for each chromosome reflects the relative length of each 
chromosome. Hearts were harvested from 146 mice after 18 weeks on a high-fat, cholic acid diet. 
Colored lines show permutation-derived significance thresholds (N=1000) at P = 0.05 
(LOD=7.57, shown in red), P = 0.10 (LOD=7.17, shown in orange), and P = 0.63 (LOD=5.79, 
shown in yellow).  The eight coefficients of the QTL model show the effect of each founder 
haplotype on the phenotype. A/J founder alleles are associated with larger lesion size in the DO 
mice (B.). There are 6 candidate genes within the 100,000kb QTL interval on Chromosome 6, 
Apobec1, Gdf3, Dppa3, Nanog, Slc2a3, and the predicted gene Gm26168 (C.). Gene expression 
data was obtained from livers from female C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, 
CAST/EiJ, PWK/PhJ and 129S1/SvImJ mice (http://cgd.jax.org/gem/strainsurvey26). There are 
six candidate genes in the QTL interval on Chromosome 6, Apobec1, Gdf3, Dppa3, Nanog, 
Slc2a3, and the predicted gene Gm26168, of which four, Apobec1 (D.), Gdf3 (E.), Dppa3 (F.), 
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and Nanog (G.), were assayed by microarray for hepatic gene expression. Apobec1 is the only 
candidate in this region that matches our allele effects such that A/J mice appear to express 
higher levels of Apobec1. 
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Figure 2.9- A/J preferentially expresses the long isoform of Apobec1 in response to a high-
fat, cholic acid diet. Apobec1 expression levels of the short (A.) and long (B.) isoforms from 
RNA from liver tissue from A/J and C57/BL6 founder strains. A/J mice on a high-fat, cholic acid 
diet exhibit increased expression of both the long and short transcripts of Apobec1 in a diet-
dependent manner, * indicates p> 0.05. Apobec1 levels for each sample were normalized relative 
to RPS20. Fold changes are reported as the relative expression in A/J versus C57/BL6 samples.  
Data are presented as mean + SD and significance was determined using a Student’s t-test. 
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Figure 2.10: Identification of a cis eQTL on Chromosome 6 for Apobec1 expression. The 
Jackson Laboratory’s Diversity Outbred eQTL viewer data located at 
http://cgd.jax.org/apps/eqtlviewer-beta/ was queried for eQTL associated with Apobec1 mRNA 
expression. A cis eQTL on Chromosome 6 was identified as associated with Apobec1 expression 
in the DO mice (LOD= 11.7). The eight coefficients of the QTL model show the effects on the 
phenotype contributed by each founder haplotype on Chromosome 6 (B.). These data 
demonstrate that A/J alleles are associated with higher expression of Apobec1. 
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Figure 2.11- Cis-eQTL for hepatic Apobec1 short and long isoforms in the DO mice. 
Genome-wide QTL scan for eQTL regulating expression of the short (A.) and long (B.) Apobec1 
isoforms in the DO mice. Chromosomes 1 through X are represented numerically on the x-axis 
and the y-axis represents the LOD score. The relative width of the space allotted for each 
chromosome reflects the relative length of each chromosome. Colored lines show permutation-
derived significance thresholds at P = 0.05 (red), P = 0.10 (orange), and P = 0.63 (yellow). The 
eight coefficients of the QTL model show the effects on the phenotype contributed by each 
founder haplotype on Chromosome 6 for mapping of the short (C.) and long (D.) isoforms of 
Apobec1. Shading identifies the 95% Bayesian credible interval around the peak. 
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Figure 2.12- Apobec1 and ApoB levels are dependent on the genotype of UNC11996440, the 
Chromosome 6 peak SNP associated with atherosclerosis. Genotyping was performed using 
the Mouse Universal Genotyping Array (MegaMUGA). Apobec1 mRNA levels were measured 
by QPCR from liver tissue from the DO mice. Expression levels of the Apobec1 long isoform 
differed significantly between genotype classes (p >0.001) (A.). ApoB protein levels were 
measured in a subset of the mice phenotyped for atherosclerosis (N=80 mice) using a mouse 
Apolipoprotein B Sandwich-ELISA method in 96-well format. ApoB expression levels differed 
significantly between the genotype classes (B.). 
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Product # D10001 D12083101 D12109C 
% gm kcal gm kcal gm kcal 
Protein 20.3 20.8 40.6 40 22.5 20 
Carbohydrate 66.0 67.7 40.6 40 45 40 
Fat 5.0 11.5 9.1 20 20 40 
Total 91.3 100 90.3 100 87.5 100 
kcal/gm 3.90   4.07   4.5   
              
Ingredient gm kcal gm kcal gm kcal 
Casein, Lactic 0 0 400 1600 200 800 
Casein, 30 Mesh 200 800 0 0 0 0 
L-Cystine 0 0 6 24 3 12 
DL-Methionine 3 12 0 0 0 0 
              
Corn Starch 150 600 212 848 212 848 
Maltodextrin 10 0 0 71 284 71 284 
Sucrose 500 2000 113 452 113 452 
              
Cellulose, BW200 50 0 50 0 50 0 
              
Corn Oil 50 450 0 0 0 0 
Soybean Oil 0 0 25 225 25 225 
Cocoa Butter 0 0 66 594 155 1395 
              
Mineral Mix S10001 35 0 0 0 0 0 
Mineral Mix S10021 0 0 10 0 10 0 
Dicalcium Phosphate 0 0 13 0 13 0 
Calcium Carbonate 0 0 5.5 0 5.5 0 
Potassium Citrate 0 0 16.5 0 16.5 0 
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Vitamin Mix 
V10001 10 40 10 40 10 40 
Choline Bitartrate 2 0 2 0 2 0 
              
Cholesterol 0 0 0 0 11.25 0 
Sodium Cholate 0 0 0 0 4.5 0 
              
Red Dye 0 0 0 0 0.05 0 
Blue Dye 0 0 0.05 0 0.05 0 
Yellow Dye 0 0 0.05 0 0 0 
              
Total 1000 3902 1000.1 4067 901.85 4056 
 
Table 2.1: Compositions of the AIN-76A (D10001), high protein (D12083101), and 
atherogenic (D12109C) diets used in the study. 
The three diets used in this study were manufactured by Research Diets. AIN-76A was fed to the 
study population from 4-6 weeks of age in order to ensure that there were no spurious effects due 
to the potential variable composition of standard laboratory chow. Mice were then fed either 
D12109C or D12083101 for 18 weeks from 6-24 weeks of age. These diets differed by 
composition, specifically in terms of fat: protein ratio and cholesterol content, D12083101 
containing 5% fat and 20.3% protein and D12109C containing 20% fat, 1.25% cholesterol, and 
0.5% cholic acid. D12109C is considered atherogenic and was intended to induce the formation 
of atherosclerosis in the DO mice.  
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Baseline (AIN-
76A)   High Protein   High-fat, cholic acid 
  n Mean 
 
n Mean 
 
n Mean 
Cholesterol 
(mg/dl) 277 91.7 ± 25.1   128 97.6 ±31.5**   136 199.9 ± 68.6*,** 
Triglyceride
s (mg/dl)  262 59.5 ± 26.5   128 57.7±30.8**   136 32.3 ±12.1*,** 
Glucose 
(mg/dl) 257 155.2 ± 43.8   130 190.5 ±49.9   137 177.9 ± 45.1 
Insulin 
(ng/ml) 235 0.8 ± 0.4   129 1.7±1.1*   133 1.4 ± 0.7* 
  
 
              
  
*Significant difference between baseline diet and post diet 
group, p < 0.05 
**Significant difference between post diet groups, p < 0.05       
 
Table 2.2: Effects of high protein and high-fat, cholic acid diets on clinical markers of 
cardiovascular disease in the DO mice. 
The values shown are means + SD. Plasma clinical chemistries were measured at baseline, after 
two weeks on the synthetic defined diet AIN-76A, and with 4 hours fasting (in 6 week old mice). 
Mice were transferred to one of two diets, either a high-fat, cholic acid diet or a high protein diet, 
and maintained on diet for 18 weeks. Plasma clinical chemistries were measured again after diet 
treatment and with 4 hours fasting (in 24 week old mice). Significant differences between the 
baseline diet measures and either diet treatment group (*, where p < 0.05) or significant 
differences between the two different diets after 18 weeks of diet treatment (**, where p < 0.05) 
are indicated. 
 
  
61 
 
 
  Phenotype Chr Peak 
LOD 
 Position 
(Interval) 
Significant 
(p< 0.05) 
Previously 
Known QTL 
(Interval) 
Known 
Gene 
Candidates 
Refs. 
  
_
 B
a
se
li
n
e_
_
 
Triglycerides 9 11.3 51.4 (50.2-
51.6 Mb) 
Y Trigq1 (40-70 
Mb) 
ApoA5 Suto, 2003 
Total 
Cholesterol 
13 6.5 30.4 (28.7-
43.8 Mb) 
N Hmgcs1 (20-
100 Mb) 
Hmgcr Welch, 
1996 
Glucose 5 7.0 92.6 (86.3-
99.0 Mb) 
N Bglu13 (84-
110 Mb) 
Hnf1a, Pdx1 Zhang, 
2012 
Insulin 19 5.4 58.6 (22.6-
60.8 Mb) 
N Tanidd1 (36-
61 Mb) 
Not 
Determined 
Kim, 2001 
  
  
 A
ft
er
 d
ie
t_
_
 
Triglycerides 12 5.8 97.6 (49.6-
102.3 Mb) 
N Tglq2 (55-89 
Mb) 
ApoB Srivastava, 
2006 
Total 
Cholesterol 
9 7.5 48.3 (47.8-
70.0 Mb) 
Y Cq4 (15-50 
Mb), Cq5 
(32-66 Mb)  
ApoA4 Suto, 2003 
Glucose 12 5.7 70.9 (26.7-
75.1 Mb) 
N Bglu15 (10-
42 Mb) 
Adam17 Zhang, 
2012 
Insulin 13 7.0 8.7 (5.7-
10.4 Mb) 
N NA NA NA 
 
Table 2.3: Quantitative trait loci for clinical markers of cardiovascular disease in the DO 
mice at baseline and after dietary treatment. 
Clinical markers of cardiovascular disease were measured in study animals after 4 hours of 
fasting at both 6 weeks and 24 weeks of age. Baseline measures are from 6-week-old fasted mice 
fed a synthetic diet. Measures at 24 weeks of age, after diet, include mice on both the high 
protein diet and the high-fat, cholic acid diet; diet was used as a covariate in the analysis. The 
statistic reported is log of the odds ratio (LOD).  
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CHAPTER 3
2
: IDENTIFICATION OF NUMB AS A POTENTIAL GENETIC 
REGULATOR OF THE ATHEROSCLEROSIS-ASSOCIATED METABOLITE 
TRIMETHYLAMINE-N-OXIDE IN DIVERSITY OUTBRED MICE 
 
CHAPTER OVERVIEW 
Dietary choline and its derivatives have been associated with various aspects of lipid 
metabolism. Recently, the choline metabolite trimethylamine-N-oxide (TMAO) has been 
associated with atherosclerosis in both mice and humans. Traditional studies of atherosclerosis in 
mice use genetic or dietary manipulation to induce atherosclerosis in inbred mouse strains. 
Inbred mice exhibit strain-specific variation in susceptibility to atherosclerosis and dyslipidemia 
rendering them useful as models in the dissection of the genetic architecture of these complex 
diseases. However, traditional quantitative trait locus (QTL) mapping studies using inbred strains 
often identify large genomic regions, containing many genes, due to limited recombination 
and/or sample size which hamper candidate gene identification and translation of these results 
into possible risk factors and therapeutic targets. As an alternative approach, here we use the 
multi-parental Diversity Outbred (DO) mouse panel for genetic mapping in order to aid in the 
identification of causal genes and variants associated with TMAO. We mapped QTL for choline 
metabolites using a linear regression model [101]. Among our highly significant hits, we 
detected a 4.6 Mb QTL interval on Chromosome 12 with a peak at 86.3 Mb (LOD= 10.0, 
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p<0.05) for the atherosclerosis-associated metabolite trimethylamine-N-oxide at baseline which 
was also identified as a suggestive QTL after dietary treatment (LOD= 6.7, p<0.1). The 
Chromosome 12 QTL associated with TMAO contains the positional candidate gene Numb, 
which encodes a clathrin adapter with a role in endocytosis that was recently shown to modulate 
intestinal cholesterol absorption. We show that TMAO and Numb exhibit inverse strain variation 
across the DO founder strains and that the novel Chromosome 12 TMAO locus co-localizes with 
a highly significant cis-expression QTL for Numb, indicating a potential functional relationship. 
INTRODUCTION 
Dietary choline and its derivatives have been associated with various aspects of lipid 
metabolism [132-134]. Several papers published in the last few years have indicated that 
intestinal microbiota metabolism has an impact on cardiovascular disease risk and the 
development of atherosclerosis [70, 135-139]. Specifically, Wang et al. published a pivotal paper 
in 2011 in which they identified choline and two of its metabolites, trimethylamine-N-oxide 
(TMAO) and betaine, as predictive of cardiovascular disease events in humans. They went on to 
show that in mice, dietary supplementation with choline or TMAO promoted atherosclerotic 
lesion development [70]. The results of choline challenge studies in humans in which TMAO 
levels were found to be elevated after ingestion of hard-boiled eggs corroborated the initial 
findings that elevated TMAO levels predicted an increased risk of cardiovascular disease events 
[140]. Additionally, researchers showed that administration of antibiotics suppressed TMAO 
levels, indicating the vital role of the microbiota as a first line of regulation in monitoring 
circulating TMAO levels [136]. In addition to regulation by gut microbiota, there is increasing 
evidence that host genetics plays a role in the regulation of TMAO levels [72, 93, 141]. 
TMAO is derived from microbiota metabolism of dietary choline and 
phosphatidylcholine. Choline-containing compounds are metabolized by the gut flora in the 
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intestines to produce an intermediate compound, TMA, which is then absorbed into the host 
circulation and neutralized to TMAO primarily by FMO3 in the liver [72, 141]. Aside from the 
regulation by FMO3, little is known about how the host genetics interact with and regulate 
circulating TMAO levels.  
A recent genome-wide association study using the hybrid mouse diversity panel 
identified a Chromosome 3 locus associated with TMAO levels and implicated a potential role 
for the solute carrier family 30 member 7 (SLC30A7) protein, although a functional relationship 
has yet to be determined. The same study identified two QTL on human chromosomes 1q23.3 
and 2p12 with suggestive evidence of association with plasma TMAO levels [93]. Fmo3 is 
located on mouse Chromosome 1 and, although it is known to regulate TMAO levels, Fmo3 has 
not been identified in genetic mapping studies of plasma TMAO levels, possibly due to the 
absence of genetic variation around the Fmo3 locus.  
Studies to identify additional genetic regulators of TMAO levels will be important to 
further elucidate the impact of host genetics on regulation of TMAO. Here, we utilized the newly 
developed DO mouse population specifically designed for high resolution genetic mapping to 
identify novel genetic regulators influencing TMAO levels which could present potential 
therapeutic targets for CVD in humans. 
MATERIALS AND METHODS 
Animals and Diets 
Female Diversity Outbred mice (n = 292; J:DO, JAX stock number 009376) were 
obtained from the Jackson Laboratory (Bar Harbor, ME) as 146 full sibling pairs at 4 weeks of 
age and at outbreeding generation 11 (G11) (received September, 2012). The mice were group 
housed (n = 5 mice per cage) with non-irradiated pine bedding and provided with HEPA-filtered 
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air and free access to sterile water in a climate-controlled facility under a 12 hour light:dark 
cycle. Mice were maintained on a defined synthetic diet, AIN-76A, until 6 weeks of age to 
control for differences due to variable components of standard chow (D10001, Research Diets, 
New Brunswick, NJ); subsequently, 146 mice were transferred to a synthetic high-fat, cholic acid 
(HFCA) diet, containing 20% fat, 1.25% cholesterol, and 0.5% cholic acid, to induce 
atherosclerotic lesions and 146 mice were maintained on a high protein diet containing 5% fat 
and 20.3% protein which is not atherogenic (D12109C and D12083101, respectively, Research 
Diets, New Brunswick, NJ). One sibling from each of the 146 sibling pairs was randomly 
assigned to each one of the diets. The source of fat from the diets varied between the baseline 
diet (corn oil) fed to the mice from 4 to 6 weeks of age and the dietary treatment groups (soybean 
oil plus cocoa butter) fed to the mice from 6 to 24 weeks of age. All mice were maintained on 
their respective diets until 24 weeks of age, for a total of 18 weeks. All procedures were 
approved by the IACUC at UNC Chapel Hill (IACUC Protocol Number 11-299). 
Measurement of Choline Metabolites 
Measurement of choline metabolites was performed by the Metabolomics Core Facility 
(Kannapolis, NC). In brief, plasma was extracted with three volumes of acetonitrile spiked with 
internal standards TMAO-d9 (DLM-4779-1, Cambridge Isotope Laboratories), creatinine-d3 (D-
3689, CDN Isotopes Inc.), choline-d9 (DLM-549-1, Cambridge Isotope Laboratories) and 
betaine-d9 (616656, Sigma-Aldrich), incubated on ice for 10 minutes, and centrifuged at 15,000 
g for 2 minutes. Quantification of TMAO, creatinine, choline and betaine was performed using 
liquid chromatography-stable isotope dilution-multiple reaction monitoring mass spectrometry 
(LC-SID-MRM/MS). Chromatographic separations were performed on an Atlantis Silica HILIC 
3µm 4.6×150mm column (Waters Corp, Milford, USA) using a Waters ACQUITY UPLC 
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system. The column was heated to 40°C, and the flow rate was maintained at 1 mL/min. The 
gradient was 5% A for 0.05 min, to 15% A in 0.35 min, to 20% A in 0.6 min, to 30% A in 1 min, 
to 45% A in 0.55 min, to 55% A in 0.05 min, at 55% A for 0.9 min, to 5% A in 0.05 min, at 5% 
A for 1.45 min, where A is 10% acetonitrile/90%water with 10 mM ammonium formate. The 
metabolites and their corresponding isotopes were monitored on a Waters TQ detector using 
characteristic precursor-product ion transitions: 7658 for TMAO, 8566 for TMAO-d9, 
11486 for creatinine, 11789 for creatinine-d9, 10445 for choline, 11345 for choline-d9, 
11859 for betaine, and 12768 for betaine-d9. Concentrations of each metabolite in samples 
were determined from its calibration curve using peak area ratio of the metabolite to its isotope. 
Significant differences between groups were determined using a Student’s t-test. 
Genotyping  
DNA was extracted and purified from tail biopsies taken from 6-week-old mice using 
Qiagen DNeasy kit according to the manufacturer’s instructions. Genotyping was performed 
using the Mega Mouse Universal Genotyping Array (MegaMUGA) by GeneSeek (Neogen, 
Lansing, MI) [113]. The call rate exclusion criteria was set at >95% and twelve mice were 
excluded based on this criteria; the average call rate of the genotyped mice used in the study was 
98%. The MegaMUGA array is built on the Illumina Infinium platform and contains 77,808 SNP 
markers that are distributed throughout the genome at an average spacing of 33 Kb. The 
MegaMUGA SNPs were subset to include 57,977 informative SNPs that distinguish among the 
genotypes of the eight founder strains.  For the mapping, genomes were reconstructed based on 
the X and Y allele intensities from the array and founder haplotypes were reconstructed using a 
hidden Markov model. The founder allele dosages based on the reconstructed haplotypes were 
then used to perform linkage mapping. 
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QTL Mapping 
QTL mapping was performed using DOQTL Bioconductor release version 1.0.0 for the R 
environment [101]. DOQTL reconstructs the genomes of the DO mice in terms of 8 state founder 
allele dosages and performs QTL mapping by regressing the phenotypes on the founder allele 
dosages of the condensed additive haplotype model with the assumption that the effects of the 
founder alleles are additive. Phenotypes were natural log-transformed to satisfy the model 
assumption of a normal distribution. Diet was included as an additive covariate in the mapping 
model for measurements including phenotypes obtained from 24 week old mice after dietary 
treatment. Candidate genes were identified by position based on the Wellcome Trust Sanger 
mouse genomes database, www.sanger.ac.uk, release 1303 based on genome assembly GRCm38 
[114]. QTL support intervals were defined by the 95% Bayesian credible interval, calculated by 
normalizing the area under the QTL curve on a given chromosome [115]. The mapping statistic 
reported is log of the odds ratio (LOD). The significance thresholds were determined by 
performing 1000 permutations of genome-wide scans by shuffling phenotypic data in relation to 
individual genotypes. Significant QTL were determined at a genome-wide p-value of <0.05 and 
suggestive QTL were determined at a p-value of <0.63. The latter corresponds to one false 
positive per genome scan [116]. 
Differential expression of genes in peak regions across the founder strains 
Publicly available expression data for candidate genes from liver tissue of female 
C57BL6/J, A/J, NOD/ShiLtJ, NZO/HiLtJ, WSB/EiJ, CAST/EiJ, PWK/PhJ and 129S1/SvImJ 
mice (http://cgd.jax.org/gem/strainsurvey26/v1) were obtained from The Jackson Laboratory 
Gene Expression Strain Survey and analyzed in R to determine differential expression. Mice 
included in the Jackson Laboratory Gene Expression Survey were maintained for 11 weeks on 
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standard chow diet (4% fat content). Genes were identified as differentially expressed between 
the DO founder strains using analysis of variance and significant between strains differences 
were calculated using Tukey’s Post Hoc test. We used a Bonferroni correction to determine 
statistical significance and correct for multiple comparisons.  
Numb mRNA expression in the DO mice 
QPCR was performed in triplicate using a High Capacity Reverse Transcriptase Kit 
(Applied Biosystems, Foster City, CA). Following cDNA conversion, 1 µL of sample cDNA, 2 
µL KAPA Sybr Fast qPCR mastermix (KK4610), and 0.5 µM primers was added to each well of 
a 384-well plate. Numb primers were custom designed and ordered from Eurofins MWG Operon 
(Huntsville, AL). Amplification was performed using the following primer set 5’- 
caccacagtctcctgtgttacaa-3’ (left primer) and 5’-cagtattggctggcttagcagt-3’ (right primer). This 
primer set was designed to recognize the known Numb transcripts Numb-002 and Numb-003 
(ENSMUST00000129335.1 and ENSMUST00000154043.1, respectively). A serial dilution of 
pooled samples was used to create a standard curve. Sterile water was used as a negative control.    
RESULTS 
Metabolites are important metabolic intermediates that represent intermediate phenotypes 
between DNA variation and clinical phenotypes. TMAO is a common metabolite found in 
mammals that has recently been identified as a clinical predictor of atherosclerosis [134, 140, 
142, 143]. TMAO levels are regulated through both the microbiome and through host genetics, 
though the influence of host genetics on TMAO levels is not yet fully understood [72, 93]. 
Therefore, we were interested in gaining a better understanding of genetic regulators of choline 
metabolism by identifying novel genetic regulators of TMAO and choline.  
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Changes in choline metabolites in response to diet 
Our lab has previously shown strain-specific variation in TMAO levels across the eight 
progenitor strains used to generate the DO mice [144]. Here, we were interested in evaluating the 
extent of variation of TMAO and its precursor molecule choline in the DO mice. Mice were 
maintained on a synthetic diet from 4 to 6 weeks of age. From 6 weeks to 24 weeks of age, one 
mouse from each sib-pair was randomly assigned to either the HFCA diet group or the HP diet 
group. At baseline, while all mice were still on a controlled, synthetic diet, choline levels 
differed slightly between the mice assigned to the atherogenic diet versus the high protein diet 
(p<0.001), and this difference was still apparent after diet treatment (p<0.05). In response to diet, 
the mice on the high protein diet exhibited no change in choline levels, while the mice on the 
atherogenic diet exhibited a significant decrease in choline levels (p<9 x 10
-10
), Figure 3.1A. 
There was no difference in TMAO levels between the mice from each of the diet groups at 
baseline. However, after 18 weeks on different diets, we observed a highly significant increase in 
TMAO levels in response to the atherogenic diet (p<4 x 10
-21
); while TMAO levels in the mice 
maintained on the high protein diet did not differ from the baseline levels, Figure 3.1B. 
Identification QTL on Chromosome 12 associated with choline in 24 week old mice 
Choline was measured in the mice at both 6 weeks and 24 weeks of age. While we 
identified only a suggestive QTL on Chromosome 12 (LOD= 7.3, p< 0.1) associated with 
choline levels in mice at baseline, Table 3.1, we identified a significant QTL on distal 
Chromosome 12 (LOD=7.8, p< 0.05) associated with choline in mice after dietary treatment, 
Figure 3.2A. The significant Chromosome 12 QTL has a 4.3 Mb support interval with a peak 
SNP at 116.8 Mb (113.2-117.5 Mb). By plotting the founder allele coefficients from the additive 
haplotype model, we can visualize the effect of each founder haplotype on the phenotype. Based 
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on the founder allele effects, mice with allelic contribution from the C57BL/6J, 129S1/SvImJ, 
NOD/ShiLtJ, NZO/HiLtJ, and CAST/EiJ founders within the QTL interval have higher choline 
levels, while mice with allelic contribution from A/J and PWK/PhJ within the QTL interval 
exhibit lower choline levels, Figure 3.2B. This strain distribution pattern suggests that a SNP 
shared by and unique to A/J and PWK/PhJ may be causal at this locus. There are 68,162 SNPs 
within the Bayesian credible interval and only 234 have alleles shared by A/J and PWK/PhJ that 
are different from C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and CAST/EiJ, consistent 
with the allele effects we observed suggesting one of these SNPs may be causally associated 
with regulation of choline. There are 31 positional candidates within this QTL interval, Figure 
3.2C.  
Identification of Chromosome 14 QTL associated with TMAO at baseline  
We identified a novel QTL on Chromosome 14 (LOD= 8.2, p <0.05) that was associated 
with TMAO levels at baseline, Figure 3.3A. Based on the founder allele effects we observed, 
C57BL/6J,129S1/SvImJ, CAST/EiJ, PWK/PhJ alleles in this interval are associated with higher 
TMAO levels, while A/J, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ alleles in this interval are 
associated with lower TMAO levels, Figure 3.3C. There are 233,673 SNPs within the Bayesian 
credible interval. 23,108 SNPs are shared by A/J, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ and 
these are located throughout the interval, from 86,148,966-94,774,798 Mb. Therefore, we are 
unable to narrow down the genes of interest based on the allele effects within this region. While 
the Chromosome 14 QTL is 16.3 Mb in size, it is located in a region of relatively few coding 
genes and there are 49 positional candidates within the interval, Figure 3.3E. 
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Identification of Chromosome 12 QTL associated with TMAO at baseline and after dietary 
treatment 
We identified a novel QTL on Chromosome 12 that was associated with TMAO levels at 
baseline and after dietary treatment, Figure 3.3A and 3.4A, respectively. In 6 week old mice, the 
Chromosome 12 QTL is significantly associated with TMAO levels (LOD=10.0, p< 0.05), 
Figure 3.3A. This QTL has a 4.6 Mb (83.6-88.2 Mb) support interval and contains 116 genes, 
Figure 3.3C. Based on the founder allele effects, we see that allelic contribution from A/J, 
C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ within the interval is 
associated with the high TMAO levels, while allelic contribution from CAST/EiJ and PWK/PhJ 
alleles within the interval are associated with low TMAO levels, Figure 3.3B. While the allele 
effects within the QTL interval can often be used to narrow down the list of candidate genes to 
those genes that have expression matching the allele effects or functional variants exhibiting the 
same strain distribution pattern, CAST/EiJ and PWK/PhJ are wild-derived strains and they 
contribute many private alleles that span the entire QTL interval. Indeed, of the 61,363 
genotyped SNPs within the 4.6 Mb interval, 15,386 match our allele effects and are shared by 
and unique to CAST/EiJ and PWK/PhJ. Further characterization of SNPs within the interval 
indicates that there are 259 3’ UTR SNPs, 55 5’ UTR SNPs, 78 non-synonymous SNPs, 26 
splice variants, 16 insertions, and 35 deletions spanning the QTL interval (between 83,569,930-
88,217,420 Mb) that are shared by CAST/EiJ and PWK/PhJ (www.sanger.ac.uk), Table 3.2.  
We identified the same QTL on Chromosome 12 (LOD= 6.7, p <0.05) as associated with 
TMAO after dietary treatment, though it did not reach genome-wide significance after diet 
Figure 3.4A. The allele effects for the QTL also indicate that allelic contribution from CAST/EiJ 
and PWK/EiJ within the interval is associated with low circulating TMAO levels, while allelic 
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contribution from A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ within 
the interval is associated with the high TMAO levels Figure 3.4B. The QTL for TMAO after 
dietary treatment has a 3.8 Mb (83.1 Mb- 87.1 Mb) support interval with a peak SNP at 85.7 Mb, 
less than 1 Mb from the peak SNP associated with TMAO in mice at 6 weeks of age, and the 
interval contains 85 positional candidates, Figure 3.4C. These results suggest that a SNP shared 
by CAST/EiJ and PWK/EiJ is likely causal for the association and that the gene underlying the 
association is influenced by diet.  
Differential expression of TMAO positional candidates 
Because the Chromosome 12 QTL associated with TMAO was highly significant and 
appeared to be affected by diet, we decided to prioritize this QTL for candidate gene testing. In 
addition to a causal variant resulting in a structural change in a gene associated with TMAO 
levels, this QTL could be due to a variant influencing expression of the causal gene. We 
hypothesized that if the QTL we have identified results from altered gene expression of the 
causal gene, then we may be able to narrow our list of candidate genes by cross referencing the 
allele effects in our DO study population with expression levels among the founder strains. We 
compared the hepatic gene expression among the founder strains for the genes in the region for 
which expression data was available (http://cgd.jax.org/gem/strainsurvey26).  
Based on the hepatic expression levels, we identified candidate genes within the QTL that 
were differentially expressed across the founder strains and then looked for the differentially 
expressed genes that most closely matched these allele effects patterns observed in our DO study 
population. Of the genes in this locus, 60 were quantitated by microarray and 37 of these were 
differentially expressed between all strains. The 8 most differentially expressed genes are: Gstz1, 
Entpd5, Ahsa1, Rps6kl1, Ttll5, Esrrb, Numb, and Dlst, Figure 3.5A-H. Gstz1 and Entpd5 
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exhibited lower expression in CAST/EiJ mice, but not in PWK/PhJ, compared to the other strains 
(3- and 4-fold lower levels in the CAST/EiJ strain compared to all other strains, respectively). 
Likewise, Dlst was more highly expressed in CAST/EiJ, but not PWK/PhJ compared to the other 
strains (1.5-fold higher in the CAST/EiJ strain compared to all other strains). Of the 8 
differentially expressed genes, Numb is the only candidate gene that matches the allele effects 
patterns we see based on the founder coefficients and is expressed at 1.4-fold lower levels in 
CAST/EiJ and 1.5-fold lower in PWK/PhJ when compared to the average Numb expression 
exhibited by the other 6 founder strains.  
Identification of a highly significant cis-eQTL for Numb on Chromosome 12 
We next measured Numb mRNA expression specifically by QPCR. We hypothesized that 
if Numb is causally associated with TMAO and being regulated at the level of expression, Numb 
expression would also map to Chromosome 12. We measured mRNA expression of the major 
isoforms of Numb from liver tissue from the DO mice and performed QTL mapping using the 
additive haplotype model. We identified a highly significant cis-eQTL on Chromosome 12 with 
the peak SNP UNC21514106 located at 83.6 Mb and with a maximum LOD score of 36.2, 
Figure 3.6A. When we estimate the effect of each founder at each marker along Chromosome 
12, we see that both CAST/EiJ and PWK/PhJ alleles are associated with higher expression of 
Numb, Figure 3.6B. Taken together, these results indicate that mice contributing CAST/EiJ and 
PWK/PhJ alleles within the QTL interval on Chromosome 12 have higher expression of Numb 
and exhibit lower circulating TMAO levels. Consistent with this finding, Numb expression and 
TMAO levels are highly negatively correlated in the DO mice at both 6 weeks (r= -0.65) and 24 
weeks (r= -0.40), Table 3.3.  
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We identified 15,386 CAST/EiJ and PWK/PhJ shared SNPs within the QTL on 
Chromosome 12 associated with TMAO at baseline, including many non-synonymous coding 
SNPs, splice variants, insertions, deletions, as well as SNPs in noncoding regions which may 
influence transcription factor binding and regulation of expression, Table 3.2. Of the 259 
CAST/EiJ and PWK/PhJ shared 3’ UTR SNPs, 14 are located in the 3’ UTR of Numb. Of the 78 
CAST/EiJ and PWK/PhJ shared non-synonymous coding SNPs, two are located in the coding 
region of the Numb gene, including a T G at 83,797,280 (no rs#) and an A  G at 83,801,288 
resulting in a valine to alanine substitution. Of the 16 CAST/EiJ and PWK/PhJ shared insertions 
and the 35 CAST/EiJ and PWK/PhJ shared deletions; there are two insertions and one deletion in 
the Numb gene. Within 10 kb of Numb, there are many additional SNPs shared by CAST/EiJ and 
PWK/PhJ and it is currently unclear which SNPs may be causally associated with TMAO, Table 
3.4. 
In conclusion, here we have identified here two novel QTL associated with TMAO in the 
DO mice. The Chromosome 12 QTL colocalizes with a highly significant cis-eQTL for the gene 
Numb. Numb encodes a clathrin adaptor with a reported role in NPC1L1-dependent endocytosis 
[145]. Consistent with the known function of Numb in mediating intestinal cholesterol 
absorption, we observe that Numb expression is highly correlated with cholesterol in our cohort 
of DO mice (r= 0.81), Table 3.3. We report here that Numb is highly negatively correlated with 
TMAO in these mice, consistent with the founder allele effects we observed. These results and 
the colocalization of QTL for plasma TMAO and Numb mRNA expression, suggest that Numb 
may play a role in the regulation of TMAO by host genetics. Additional studies investigating the 
association between Numb and TMAO and the functional relevance of this association should be 
pursued.   
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DISCUSSION 
 Metabolites are produced in the cell as a result of various enzymatic reactions and in part 
reflect the metabolic state of the cell and in some instances are used as biomarkers for human 
disease [146, 147]. We were particularly interested in choline and its metabolites because, in 
collaborative studies, we identified choline and its metabolite TMAO as predictive of 
cardiovascular disease events in humans [72, 134]. TMAO has been shown to promote 
atherosclerotic lesion development in mice and this metabolite exhibits complex regulation by 
both the gut microbiota and host genetics [72, 93, 134]. To date, there has been one QTL 
identified on mouse chromosome 1 as significantly associated with plasma TMAO and two 
suggestive QTL identified in humans [93]. Therefore, we utilized the newly developed DO 
mouse resource to identify novel genetic regulators of choline and TMAO. 
Chromosome 12 QTL associated with choline in 24 week old mice 
We identified a significant QTL on Chromosome 12 (LOD=7.8, p< 0.05) associated with 
choline in 24 week old DO mice. Based on the founder allele effects, DO mice with allelic 
contribution from the C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and CAST/EiJ 
founders within the QTL interval have higher choline levels, while mice with allelic contribution 
from A/J and PWK/PhJ within the QTL interval exhibit lower choline levels. Therefore, we 
predict that the causal variant will have an allele shared by A/J and PWK/PhJ. We identified 234 
of the 68,162 SNPs within the QTL interval as exhibiting this strain distribution pattern. Most of 
the 234 SNPs with alleles shared by A/J and PWK/PhJ are intergenic or intronic and they are 
positioned throughout the interval, from 113,202,771-117,469,183 Mb. Any of these could 
influence the expression or splicing of nearby genes. There are 10 non-synonymous coding SNPs 
with alleles shared by A/J and PWK/PhJ in the QTL interval and these are in the following 
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genes: AC079181.3, AC160473.1, Gm16747, and Ighv6-6. These genes have all been identified 
as encoding immunoglobulin heavy chain variable regions that contribute to mounting an 
immune response against pathogens. Ighv family genes are known to undergo mutation readily to 
adapt to antigens presented by foreign bacteria and viruses [148]. Indeed, within the QTL 
interval on Chromosome 12 there are a total of 1330 non-synonymous SNPs and only 56 are in 
non-Ighv family genes and none of those are shared by A/J and PWK/PhJ, suggesting that the 
variant underlying the QTL is likely one of the 224 intergenic or intronic SNPs affecting 
expression or isoform usage of one of the positional candidates. 
Chromosome 14 QTL associated with baseline TMAO 
We identified a QTL on Chromosome 14 (LOD= 8.2, p <0.05) that spans a 16.3 Mb and 
contains only 49 positional candidate genes. Based on the founder allele effects we observed, 
C57BL/6J, 129S1/SvImJ, CAST/EiJ, PWK/PhJ alleles in this interval are associated with higher 
TMAO levels, while A/J, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ alleles in this interval are 
associated with lower TMAO levels. Based on analysis of the 233,674 SNPs in this region, we 
identified 23,108 genotyped SNPs shared between A/J, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ. 
This includes 7 non-synonymous variants matching these allele effects in the genes Diap3 and 
Tdrd3 and one non-synonymous variant specific to A/J, NOD/ShiLtJ, and WSB/EiJ in the gene 
Pcdh9.  
Diap3 encodes the Diaphanous Homolog 3 which is involved in actin remodeling. Tdrd3 
encodes the Tudor Domain Containing 3 protein which has been shown to be a scaffolding 
protein and also acts as a transcriptional activator in the nucleus. Pcdh9 is a protocadherin 
involved in cell-cell adhesion. None of these genes has been previously associated with TMAO 
or atherosclerosis.  
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Within the interval, there is one gene that has been associated with atherosclerosis, Klf5. 
Klf5 encodes Krüppel-like factor 5 which is a zinc-finger transcription factor that plays a role in 
cell proliferation in the intestinal epithelium and mediates tissue remodeling in atherosclerosis 
[149-151]. In humans, SNPs in Klf5 have been associated with risk for hypertension [149]. This 
evidence suggests that Klf5 may be an attractive candidate for modulating the relationship 
between TMAO and atherosclerosis. There are 380 documented SNPs in Klf5 
(www.sanger.ac.uk). However, none of these exhibits the same strain distribution pattern we 
identified based on the allele effects from the additive haplotype model. Therefore, while 
biologically Klf5 represents the most interesting candidate underlying the Chromosome 14 QTL, 
we do not identify SNPs matching our allele effects in this gene and we are unable to narrow 
down potential candidates among the 49 positional candidate genes based on our allele effects at 
this QTL. 
Chromosome 12 QTL associated with TMAO at baseline and after dietary treatment 
We identified a QTL on Chromosome 12 significantly associated with TMAO at baseline 
and suggestively associated with TMAO after dietary treatment. We observed that DO mice with 
CAST/EiJ and PWK/PhJ alleles within the Chromosome 12 QTL had lower TMAO levels than 
mice with A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ alleles at the 
locus. We analyzed this region for CAST/EiJ and PWK/PhJ private SNPs and missense variants, 
CAST/EiJ and PWK/PhJ are two of the three wild-derived strains used to create the DO and 
carry many private SNPs compared to the other inbred strains. Therefore, we identified 
numerous SNPs shared by these strains as well as non-synonymous mutations in 38 of the 116 
genes. It is possible that a SNP shared by CAST/EiJ and PWK/PhJ results in a functional variant 
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in one of the genes within this locus and the 38 genes with missense variants shared by 
CAST/EiJ and PWK/PhJ cannot be ruled out as potential candidates.  
We also looked at expression of the genes in this region. We compared the hepatic gene 
expression among the founder strains for the genes in the region using the publicly available 
Jackson Strain Expression Survey (http://cgd.jax.org/gem/strainsurvey26). We identified the 8 
most differentially expressed genes as Gstz1, Entpd5, Ahsa1, Rps6kl1, Ttll5, Esrrb, Numb, and 
Dlst. Of the 8 differentially expressed genes, Numb is the only candidate gene that matches the 
allele effects patterns we observed in the DO mice. We measured Numb mRNA expression from 
liver tissue from the DO mice and mapped expression of this gene to a highly significant cis-
eQTL on Chromosome 12. Interestingly, these allele effects mirror the allele effects observed for 
TMAO, suggesting that DO mice with CAST/EiJ and PWK/PhJ alleles at the Chromosome 12 
QTL specifically exhibit high levels of Numb and low levels of TMAO. Consistent with this 
finding, Numb expression is highly negatively correlated with plasma TMAO both at baseline (r= 
-0.65) and after dietary treatment (r= -0.40), Table 3.3.  
While we cannot exclude the possibility that other genes in the region are causal, we have 
identified Numb as a potential candidate gene that may play a role in regulating TMAO levels. 
Classically, Numb was identified in Drosophila for its role in cell fate determination and it 
interacts with and directly binds Notch [152]. More recently, a pivotal role for Numb in the 
intestinal absorption of cholesterol was identified via its interaction with Niemann-Pick c1-like 1 
protein (NPC1L1) [153]. Additionally, recent studies have reported that dietary supplementation 
with TMAO causes decreased mRNA expression of Npc1L1 in the mouse intestine, indicating a 
potential negative feedback loop in Npc1L1-mediated absorption, which is mediated exclusively 
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by the adaptor protein Numb [142]. Follow up studies should be conducted to determine whether 
there is a causal association between Numb and TMAO. 
In conclusion, we identify here for the first time two novel QTL associated with TMAO 
in mice. The significant QTL on Chromosome 12 was present both before and after dietary 
treatment. Based on the allele effects we observed and differential expression across the founder 
strains, we identified Numb as a high priority candidate gene underlying the association. We 
measured expression of Numb in the DO mice and identified a highly significant cis-eQTL 
regulating expression of this gene. The allele effects of the cis-eQTL mirrored the allele effects 
we observed for plasma TMAO, suggesting that CAST/EiJ and PWK/PhJ alleles within the 
Chromosome 12 QTL interval contribute to decreased TMAO levels and increased Numb 
expression. Consistent with this, TMAO and Numb are highly negatively correlated in the DO 
mice. Based on this evidence, we hypothesize that the candidate gene Numb may be regulating 
TMAO in these mice and may represent a novel pathway by which the atherosclerosis-associated 
metabolite is being regulated by host genetics. While Numb has not yet been functionally linked 
to atherosclerosis, we believe that this may represent a new pathway to the development and 
progression of atherosclerotic lesions.  
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Figure 3.1: Effects of high fat, cholic acid and high protein diets on choline and TMAO 
levels in the DO mice. Mice were maintained on a synthetic diet for two weeks, fasted for four 
hours, and then phenotyped for plasma clinical chemistries at 6 weeks of age (Baseline). 
Following two weeks of synthetic diet, mice were transferred to either a high protein diet (HP) or 
an atherogenic diet (HFCA). Plasma was taken from 24-week-old mice after 18 weeks on their 
respective diets, and with four hours fasting, and then phenotyped for plasma clinical chemistries 
after diet treatment (Treated) (*p< 0.05, **p< 0.01, ***p< 0.001, ****p< 0.0001). 
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Figure 3.2: QTL mapping of choline in the DO mice after dietary treatment. Genome-wide 
QTL scan for loci affecting choline levels after 18 weeks of dietary treatment (A). Chromosomes 
1 through X are represented numerically on the x-axis and the y-axis represents the LOD score. 
The relative width of the space allotted for each chromosome reflects the relative length of each 
chromosome.  Plasma was taken from 24-week-old mice after 18 weeks of dietary treatment. 
Colored lines show permutation-derived significance thresholds (N=1000) at P = 0.05 
(LOD=7.57, shown in red), P = 0.10 (LOD=7.17, shown in orange), and P = 0.63 (LOD=5.79, 
shown in yellow).  The eight coefficients of the QTL model show the effect of each founder 
haplotype on the phenotype. Shading identifies the 95% Bayesian credible interval around the 
peak (B.). There are 31 potential candidate genes within the Chromosome 12 locus associated 
with choline after dietary treatment (C.). 
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Figure 3.3: QTL mapping of TMAO in the DO mice at baseline. Genome-wide QTL scan for 
loci affecting choline in 6 week old mice. Chromosomes 1 through X are represented 
numerically on the x-axis and the y-axis represents the LOD score. The relative width of the 
space allotted for each Chromosome reflects the relative length of each Chromosome. Mice were 
maintained on a synthetic diet for 2 weeks and then phenotyped for plasma clinical chemistries at 
6 weeks of age. Colored lines show permutation-derived significance thresholds (N=1000) at P = 
0.05 (LOD=7.5, shown in red), P = 0.10 (LOD=7.1, shown in orange), and P = 0.63 (LOD=5.8, 
shown in yellow) (A.). The eight coefficients of the QTL model show the effect of each founder 
allele on the phenotype along Chromosome 12 (B.) and Chromosome 14 (C.). Shading identifies 
the 95% Bayesian credible interval around the peak. There are 116 potential candidate genes 
within the Chromosome 12 locus. The candidate gene Numb is highlighted in red (D.). There are 
49 potential candidate genes within the Chromosome 14 locus (E.). 
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Figure 3.4: QTL mapping of TMAO in the DO after dietary treatment mice. Genome-wide 
QTL scan for loci affecting TMAO levels after 18 weeks of dietary treatment (A). Chromosomes 
1 through X are represented numerically on the x-axis and the y-axis represents the LOD score. 
The relative width of the space allotted for each chromosome reflects the relative length of each 
chromosome.  Plasma was taken from 24-week-old mice after 18 weeks of dietary treatment. 
Colored lines show permutation-derived significance thresholds (N=1000) at P = 0.05 
(LOD=7.57, shown in red), P = 0.10 (LOD=7.17, shown in orange), and P = 0.63 (LOD=5.79, 
shown in yellow).  The eight coefficients of the QTL model show the effect of each founder 
haplotype on the phenotype. Shading identifies the 95% Bayesian credible interval around the 
peak (B.). There are 85 potential candidate genes within the Chromosome 12 locus associated 
with TMAO after dietary treatment. The candidate gene Numb is highlighted in red (C.).  
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Figure 3.5- Differentially expressed positional candidates within the Chromosome 12 QTL 
associated with TMAO. Hepatic gene expression across the DO founder strain mice. We 
identified the 8 most differentially expressed genes as Gstz1, Entpd5, Ahsa1, Rps6kl1, Ttll5, 
Esrrb, Numb, and Dlst (A.-H.). Numb most closely matches the founder allele effects identified 
by QTL mapping.  
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Figure 3.6: Identification of a cis-eQTL for Numb in the DO mice. Genome-wide QTL scan 
for eQTL regulating expression of Numb in the DO mice. Chromosomes 1 through X are 
represented numerically on the x-axis and the y-axis represents the LOD score. The relative 
width of the space allotted for each chromosome reflects the relative length of each chromosome. 
Colored lines show permutation-derived significance thresholds at P = 0.05 (red), P = 0.10 
(orange), and P = 0.63 (yellow). The eight coefficients of the QTL model show the effects on the 
phenotype contributed by each founder haplotype on Chromosome 12. Shading identifies the 
95% Bayesian credible interval around the peak (B.). Hepatic expression of Numb across the 
founder strains and the effect of the HFCA diet on Numb expression in the progenitor strain 
mice. The HFCA diet induces Numb expression in a strain-specific manner, specifically Numb 
expression was significantly increased in response to diet in 129/SvImJ, CAST/EiJ, and 
PWK/EiJ strains. 
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Table 3.1: Summary of QTL identified as associated with choline and TMAO in the DO.  
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Table 3.2: SNP analysis of Chromosome 12 QTL associated with TMAO at baseline. 
  
 
  
89 
 
Table 3.3: SNP analysis of known variants within 10 kb of the candidate gene Numb on 
Chromosome 12. 
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Table 3.4: Spearman’s correlations between Numb expression and cardiovascular traits in the 
DO mice. 
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CHAPTER 4: QUANTITATIVE TRAIT LOCUS ANALYSIS OF METABOLIC 
PHENOTYPES IN THE DO MICE 
 
CHAPTER OVERVIEW 
We performed linkage mapping in DO mice that were genotyped at using the high-
density MegaMUGA genotyping array. Linkage mapping was performed using the 8 founder 
state haplotype contributions. Mice were fed either a HFCA diet or a high protein diet for 18 
weeks and diet was included as an additive covariate in the mapping model for all traits which 
included phenotypes collected from mice at 24 weeks after dietary treatment. Here, I report and 
summarize the results of mapping 8 quantitative traits in this cohort of DO mice. We identified 
21 suggestive loci and three significant loci (p<0.05) including novel loci for measures of blood 
urea nitrogen (BUN) and insulin resistance. The QTL on Chromosome 1 associated with BUN at 
baseline encompasses a 900 kb region containing only 5 genes, including the candidate gene, 
Esrrg, which has been shown to be involved in the organization of renal papillae. We were able 
to identify a single SNP that matches out allele effects patterns that is located in an intron of 
Esrrg. The QTL on Chromosome 8 associated with HOMA-IR in 24 week old mice is 1.8 Mb in 
size and encompasses 42 positional candidate genes, including the high priority candidate Fgfr1. 
These results confirm the power of the DO to identify novel loci and fine map QTL to sub-Mb 
genomic regions containing far fewer positional candidates for follow up study, thus expediting 
efforts to identify causal genes and variants underlying the significant associations. 
 
 
92 
 
INTRODUCTION 
QTL mapping is a statistical approach used to associate genomic intervals with 
phenotypic traits. QTL mapping has been widely and successfully used to identify loci associated 
with human disease. QTL mapping studies using inbred mice have aided in the discovery of 
genes underlying many human disease associated QTL [154]. However, the use of inbred mice 
for QTL mapping is limited by the lack of allelic diversity present in inbred strains and when 
QTL intervals are identified they are often too large to quickly identify the underlying causal 
gene responsible for the genetic association, sometimes requiring many years of follow up 
studies before the causal gene is identified [155]. Recently, efforts have been made to develop 
heterogeneous and outbred populations of mice designed to be informative for QTL mapping 
studies. Mouse populations such as the HS and the DO are derived from multiple inbred founder 
strains, providing the introduction of allelic variants, and are maintained by outbreeding, 
resulting in the accumulation of recombination events at each successive generation of 
outbreeding [79, 81, 97, 98].  
The DO mice are a heterogeneous population derived from the following eight inbred 
founder strains: A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ, 
and WSB/EiJ. The DO mice are maintained by randomized outbreeding as 175 outbred lines at 
the Jackson Laboratory in Bar Harbor, Maine and at the time of this study were at outbreeding 
generation 11 (received September, 2012). The allelic diversity present in the DO population 
represents 90% of the known allelic diversity present in inbred strains. The DO contain 
approximately 45 million segregating SNPs, including 37.8 million SNPs and 6.9 million 
insertions, deletions, and structural variants [101]. Additionally, the genetic variation captured by 
the DO mice is uniformly distributed throughout the mouse genome [98]. Because the DO mice 
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are highly heterozygous outbred animals that were designed to capture the majority of known 
allelic variants across the eight inbred founder strains, which include three wild-derived strains, 
these mice have proven to be highly informative for QTL mapping studies [97, 98, 100-103, 156, 
157]. 
While multi-parent mapping populations like the DO present a more powerful resource 
for QTL mapping, they often also present new challenges in data analysis. The mosaic genomes 
of the DO mice are informative for mapping due to the accumulation of meiotic recombinations, 
but the identification of small haplotype blocks requires high-density genotyping of individual 
mice in order to accurately reconstruct haplotypes. For our study, the mice were genotyped using 
the high-density MegaMUGA array which assays 77,808 SNPs spanning the mouse genome 
which an average spacing of 33 kb (GeneSeek, 2013). For haplotype reconstructions and QTL 
mapping, we used DOQTL, which is a specialized software package that uses an HMM for 
haplotype reconstructions and uses the information from the HMM to input the founder allele 
dosages for QTL mapping [101].  
The earliest DO mapping studies had much success using DOQTL to identify QTL 
associated with phenotypes including complex traits related to cardiovascular disease and 
behavioral phenotypes [97-99]. Here, I report the results of QTL mapping of 8 additional 
quantitative traits in this cohort of DO mice not previously reported in Chapters 2 and 3. Among 
our significant findings, we identify novel loci for blood urea nitrogen and HOMA-IR, a measure 
of insulin resistance, Table 4.1. We identify a single SNP in an intron of Esrrg underlying the 
Chromosome 1 QTL associated with BUN. These results highlight the usefulness of the DO as a 
resource for QTL mapping and the identification of causal variants underlying QTL. 
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MATERIALS AND METHODS 
Animals and Diets 
Female Diversity Outbred mice (n = 292; J:DO, JAX stock number 009376) were 
obtained from the Jackson Laboratory (Bar Harbor, ME) as 146 full sibling pairs at 4 weeks of 
age and at outbreeding generation 11 (G11) (received September, 2012). The mice were group 
housed (n = 5 mice per cage) with non-irradiated pine bedding and provided with HEPA-filtered 
air and free access to sterile water in a climate-controlled facility under a 12 hour light:dark 
cycle. Mice were maintained on a defined synthetic diet, AIN-76A, until 6 weeks of age to 
control for differences due to variable components of standard chow (D10001, Research Diets, 
New Brunswick, NJ); subsequently, 146 mice were transferred to a synthetic high-fat, cholic acid 
(HFCA) diet, containing 20% fat, 1.25% cholesterol, and 0.5% cholic acid, to induce 
atherosclerotic lesions and 146 mice were maintained on a high protein diet containing 5% fat 
and 20.3% protein which is not atherogenic (D12109C and D12083101, respectively, Research 
Diets, New Brunswick, NJ). One sibling from each of the 146 sibling pairs was randomly 
assigned to each one of the diets, as previously described in Chapter 2 of this thesis. The diet 
composition, including source of fat from the diets is described in Table 2.3 of this thesis. All 
mice were maintained on their respective diets until 24 weeks of age, for a total of 18 weeks. All 
procedures were approved by the IACUC at UNC Chapel Hill (IACUC Protocol Number 11-
299). 
Plasma clinical chemistries 
At 6 weeks of age, the mice were anesthetized using isoflurane and blood was collected 
after 4 hours of fasting into EDTA-containing microtubes from the retro-orbital sinus. This was 
repeated at 24 weeks of age, after 18 weeks of dietary treatment. Blood samples were centrifuged 
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for 10 minutes at 10000 rpm at 4°C and stored at -80°C. The plasma levels of glucose, ALT, 
AST, and BUN were quantitated using a Biolis 24i Analyzer (Carolina Liquid Chemistries, 
Winston-Salem, NC). HDL was precipitated using the Heparin-MgCl
2
 precipitation method. 
Samples were run in triplicate in a 96-well plate and optical densities were measured at 515 nm 
using a microplate reader and analyzed with Gen5 Data Analysis Software (Bio-Tek, Winooski, 
VT). LDL was calculated as the difference of HDL cholesterol subtracted from total cholesterol. 
Insulin was determined using the Alpco Mouse Ultrasensitive Insulin ELISA assay (Alpco  Inc, 
Salem, NH); samples and controls were run in duplicate and optical densities were measured at 
450 nm using a microplate reader and analyzed with Gen5 Data Analysis Software (Bio-Tek, 
Winooski, VT). The homeostatic model assessment of insulin resistance (HOMA-IR)  was 
calculated using the equation [(G0 × I0)/405)], where  G0 and I0 refer to 4 hour fasting plasma 
glucose and insulin [158]. Data are presented as mean + SD and significance was determined 
using a Student’s t-test. 
Measurement of Choline Metabolites 
Measurement of choline metabolites was performed by the Metabolomics Core Facility 
(Kannapolis, NC). In brief, plasma was extracted with three volumes of acetonitrile spiked with 
internal standards TMAO-d9 (DLM-4779-1, Cambridge Isotope Laboratories), creatinine-d3 (D-
3689, CDN Isotopes Inc.), choline-d9 (DLM-549-1, Cambridge Isotope Laboratories) and 
betaine-d9 (616656, Sigma-Aldrich), incubated on ice for 10 minutes, and centrifuged at 15,000 
g for 2 minutes. Quantification of TMAO, creatinine, choline and betaine was performed using 
liquid chromatography-stable isotope dilution-multiple reaction monitoring mass spectrometry 
(LC-SID-MRM/MS). Chromatographic separations were performed on an Atlantis Silica HILIC 
3µm 4.6×150mm column (Waters Corp, Milford, USA) using a Waters ACQUITY UPLC 
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system. The column was heated to 40°C, and the flow rate was maintained at 1 mL/min. The 
gradient was 5% A for 0.05 min, to 15% A in 0.35 min, to 20% A in 0.6 min, to 30% A in 1 min, 
to 45% A in 0.55 min, to 55% A in 0.05 min, at 55% A for 0.9 min, to 5% A in 0.05 min, at 5% 
A for 1.45 min, where A is 10% acetonitrile/90%water with 10 mM ammonium formate. The 
metabolites and their corresponding isotopes were monitored on a Waters TQ detector using 
characteristic precursor-product ion transitions: 7658 for TMAO, 8566 for TMAO-d9, 
11486 for creatinine, 11789 for creatinine-d9, 10445 for choline, 11345 for choline-d9, 
11859 for betaine, and 12768 for betaine-d9. Concentrations of each metabolite in samples 
were determined from its calibration curve using peak area ratio of the metabolite to its isotope.  
Genotyping  
DNA was extracted and purified from tail biopsies taken from 6-week-old mice using 
Qiagen DNeasy kit according to the manufacturer’s instructions. Genotyping was performed 
using the Mega Mouse Universal Genotyping Array (MegaMUGA) by GeneSeek (Neogen, 
Lansing, MI) [113]. The call rate exclusion criteria was set at >95% and twelve mice were 
excluded based on this criteria; the average call rate of the genotyped mice used in the study was 
98%. The MegaMUGA array is built on the Illumina Infinium platform and contains 77,808 SNP 
markers that are distributed throughout the genome at an average spacing of 33 Kb. The 
MegaMUGA SNPs were subset to include 57,977 informative SNPs that distinguish among the 
genotypes of the eight founder strains. For the mapping, genomes were reconstructed based on 
the X and Y allele intensities from the array and founder haplotypes were reconstructed using a 
hidden Markov model. The founder allele dosages based on the reconstructed haplotypes were 
then used to perform linkage mapping. 
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QTL Mapping 
QTL mapping was performed using the R package DOQTL version 1.0.0 (DOQTL 
Bioconductor release, 2014). DOQTL reconstructs the genome in terms of founder haplotypes 
and performs QTL mapping by regressing the phenotypes on the founder haplotypes with an 
adjustment for kinship between the mice. Phenotypes were natural log-transformed to satisfy the 
model assumption of a normal distribution. Diet was included as an additive covariate in the 
mapping model for measurements including phenotypes obtained from 24 week old mice after 
dietary treatment. The mapping statistic reported is log of the odds ratio (LOD). QTL support 
intervals were defined by the 95% Bayesian credible interval, calculated by normalizing the area 
under the QTL curve on a given chromosome [115]. The significance thresholds were 
determined by performing 1000 permutations of genome-wide scans by shuffling phenotypic 
data in relation to individual genotypes. Significant QTL were determined at a genome-wide p-
value of <0.05 and suggestive QTL were determined at a p-value of <0.63. The latter 
corresponds to one false positive per genome scan [116]. Candidate genes were identified by 
position based on the Wellcome Trust Sanger mouse genomes database, www.sanger.ac.uk, 
release 1303 based on genome assembly GRCm38 [114]. Association mapping was performed 
for association of the phenotype with known SNPs within the identified QTL by imputing the 
founder SNPs onto the DO genomes.  
RESULTS 
Effects of HFCA Diet on Diversity Outbred Mice 
The overall aim of this study was to identify loci associated with atherosclerotic lesion 
development and cardiovascular risk factors in the DO mice. In order to induce lesions in these 
mice, we fed mice a synthetic HFCA diet designed to induce lesion formation but reduce adverse 
pathological effects on liver and kidney function [41]. In order to assess liver and kidney 
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function, the mice were phenotyped for ALT, AST, and BUN. Prior to dietary treatment, there 
were no significant differences in ALT, AST, or BUN in the mice at baseline, Figure 4.1. After 
dietary treatment, ALT increased significantly in response to both the high protein diet (p < 
5x10
-10
) and the HFCA diet (p < 2x10
-34
), Figure 4.1A. AST increased significantly in response 
to both the high protein diet (p < 1x10
-15
) and the HFCA diet (p < 6x10
-13
), Figure 4.1B. BUN 
increased significantly in response to both the high protein diet (p < 2x10
-19
) and the HFCA diet 
(p < 4x10
-4
), Figure 4.1C. The increase in ALT corresponds to a 3-fold increase in ALT levels in 
response to the HP diet and a 7-fold increase in response to the HFCA diet. Previous studies have 
indicated a 10-fold increase in plasma ALT as indicative of fatty liver disease [159]. While we 
did observe hepatic steatosis in some of the mice, the overall impact of the diet did not increase 
mortality. Specifically, 1% of mice died prior to the end of the study (N=5) and of those only one 
mouse was receiving the HFCA diet. 
Identification of Chromosome 1 QTL associated with BUN in 6 week old mice 
We detected two loci associated with BUN in 6 week old DO mice. A significant QTL 
interval on Chromosome 1 (LOD= 7.6, p <0.05) and a suggestive QTL interval on Chromosome 
16 (LOD= 7.2, p <0.1), Figure 4.2A. The Chromosome 1 QTL has a support interval of only 900 
kb with a peak SNP at 187.5 Mb (187.0- 187.8 Mb). The allele effects of the significant QTL 
revealed that allelic contribution from the DO founder strains A/J, C57BL/6J, and NOD/ShiLtJ is 
associated with lower BUN levels, while allelic contribution from the DO founder strains 
129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ are associated higher BUN 
levels, Figure 4.2B.  
This interval contains only 6 positional candidates, including the known genes Spata17, 
Gpatch2, and Esrrg, as well as the predicted genes Gm15509, Gm21710, and 9330162B11Rik, 
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Figure 4.2C. Of the 19,530 genotyped SNPs within the interval, only one SNP, rs32769253, is 
shared by and unique to the A/J, C57BL/6J, and NOD/ShiLtJ founders as compared to the other 
five founder strains. According to the Sanger SNP database, this SNP represents a C/T 
polymorphism located in an intron of the Esrrg gene at 187,919,386 Mb (GRC Build 38). The 
strains A/J, C57BL/6J, and NOD/ShiLtJ share a T at this position, while the strains 
129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and WSB/EiJ exhibit a shared T->C variant. 
Interestingly, Esrrg has been shown to regulate the morphology of renal papilla [160]. The 
intronic SNP we have identified here may affect enhancer binding and expression of Esrrg, 
although we cannot determine the functional relevance of this SNP without follow up studies. 
Therefore, follow up studies on the impact of this variant on Esrrg expression and more 
generally on the role of Esrrg in regulating BUN levels are warranted.   
Identification of QTL associated with HOMA-IR in 24 week old mice  
We were unable to identify loci significantly associated with independent measures of 
either insulin or glucose. These results were previously discussed in chapter 2 of this thesis, 
Table 2.3. Therefore, we decided to use measurements of fasting glucose and fasting insulin to 
calculate HOMA-IR in the DO mice. HOMA-IR is an indicator of insulin resistance that has 
been widely used clinically since it was described in the early 80s [161]. Previous work out of 
our lab identified significant strain-specific variation in HOMA-IR across the 8 founder strains 
used to create the DO, suggesting that this variation should be present in the DO mice [144]. 
Indeed, we observe HOMA-IR ranging from 0.04-1.4 in 6 week old mice fed a synthetic diet. 
Prior to transferring mice to either the HFCA or the high protein diet, there were no significant 
differences in HOMA-IR. After dietary treatment, HOMA-IR ranged from 0.03-3 in 24 week old 
mice and there were significant differences between the diet groups (p < 0.01).  
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We identified a significant QTL on Chromosome 8 (LOD= 7.7, p <0.05) associated with 
HOMA-IR in 24 week old DO mice and a suggestive QTL on Chromosome 6 (LOD= 6.6, p 
<0.63), Figure 4.3A. The Chromosome 8 QTL encompasses a 1.8 Mb interval (24.3-26.1 Mb). 
The effects of the founder alleles within this interval do not appear to fall out into two distinct 
categories. We identify C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and PWK/PhJ 
alleles within this interval as associated with high HOMA-IR levels; A/J and CAST/EiJ 
associated with intermediate HOMA-IR levels; and WSB/EiJ alleles are associated with low 
HOMA-IR levels, Figure 4.3B. This data indicates that there may be more than one SNP type 
within the interval that is associated with HOMA-IR. There are 42 positional candidates within 
this QTL interval, Figure 4.3C. There are 24,366 genotyped SNPs within the Bayesian credible 
interval including SNPs that affect splicing, SNPs in 3’ UTRs, SNPs in 5’ UTRs, non-
synonymous coding SNPs, multiple insertions and deletions, and one SNP shared by C57BL/6J 
and PWK/PhJ that results in the loss of the termination codon resulting in a long isoform of the 
gene Adam3, Table 4.3.  
While we cannot currently exclude the other 41 genes in this region as candidates, we are 
particularly interested in the gene that encodes the fibroblast growth factor receptor 1, Fgfr1, as a 
candidate gene for regulating HOMA-IR.  Fgfr1 is a transmembrane receptor which is activated 
by Fgf21 and Fgf21 has been shown to improve insulin sensitivity and reduce circulating glucose 
levels [162-164]. Additionally, the use of Fgfr1 agonists has recently been proposed for the 
treatment of metabolic syndrome and non-alcoholic fatty liver disease [164]. Therefore, Fgfr1 is 
a high priority candidate for this QTL.  
There are 1101 variants within 10 kb of the Fgfr1 gene that may regulate expression or 
function of this gene, including 25 in the 3’ UTR, 10 in the 5’ UTR, 5 splice variants, and one 
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WSB/EiJ-specific non-synonymous coding variant, Table 4.4. Based on our allele effects, we 
identified WSB/EiJ alleles within the Chromosome 8 QTL interval as associated with low 
HOMA-IR compared to the other founder strains. While this QTL could result from a change in 
expression of the causal gene, the presence of a WSB-EiJ-specific variant in Fgfr1 is intriguing. 
The non-synonymous SNP, rs47309288 at position 25,555,535 Mb, represents a TC transition 
specific to WSB/EiJ within the coding sequence of Fgfr1 resulting in a valine to alanine amino 
acid substitution that affects five of the eight protein-coding transcripts of Fgfr1. The AA 
substitution occurs at position 40 in the protein sequence resulting from the Fgfr1-001, Fgfr1-
002, Fgfr1-012, and Fgfr1-013 transcripts and at position 53 of the protein sequence resulting 
from the Fgfr1-202 transcript. The functional significance of this AA change and more generally 
of Fgfr1 in regulating insulin resistance should be further explored. 
Chromosome 9 QTL associated with change in total cholesterol exhibits complex genetic 
regulation by multiple SNP types.  
We previously reported a 22.2 Mb QTL interval on Chromosome 9 (LOD = 7.54, p 
<0.05) associated with cholesterol after dietary treatment, Figure 2.4A and Table 2.2. This 
region of Chromosome 9 has been identified as associated with triglycerides and cholesterol in 
several previous studies and the regulation of lipid metabolism by genes in this region is thought 
to be complex. The ApoA5-ApoA4-ApoC3-ApoA1 gene cluster is located at 46.2 Mb, just 
proximal to the 22.2 Mb QTL interval associated with cholesterol after dietary treatment. Here, 
we used total cholesterol levels in 6 and 24 week old mice to determine the change in total 
cholesterol from 6 to 24 weeks and then mapped this quantitative trait. We identified the same 
Chromosome 9 QTL as significantly associated with the change in total plasma cholesterol from 
102 
 
6 to 24 weeks (LOD= 7.8, p <0.05) and the 25 Mb Bayesian defined interval includes the 
ApoA5-ApoA4-ApoC3-ApoA1 gene cluster, Figure 4.5A.  
The founder allele effects in this region appear complex, likely due to multiple variants 
with different strain distribution patterns influencing the phenotype. Within the interval, 
CAST/EiJ private alleles between 45.3- 60 Mb are associated with an increase in cholesterol 
over time, while CAST/EiJ and 129S1/SvImJ shared alleles between 60-70.3 Mb are associated 
with an increase in cholesterol over time, Figure 4.5B. These results suggest that there may be at 
least two types of SNPs influencing cholesterol metabolism within this interval. In order to test 
this, we performed association mapping in the DO mice by imputing the Sanger allele calls onto 
the DO genomes. We then fit a linear regression model, similar to the additive haplotype model 
used to perform linkage mapping, but with 2-state SNP parameters in the model and estimated 
the additive effect of allelic substitution [101]. There are 91,134 CAST/EiJ-specific alleles in the 
QTL interval and 18,391 of these are highly associated with change in total cholesterol (LOD > 4 
for the additive SNP model). There are 4,314 CAST/EiJ and 129S1/SvImJ shared alleles within 
the interval and 22 of these are highly associated with change in total cholesterol (LOD > 4 for 
the additive SNP model). As expected based on our allele effects, the CAST/EiJ alleles 
associated with the phenotype are located between 47,929,312- 51,417,095 Mb and the 
CAST/EiJ and 129S1/SvImJ alleles associated with the phenotype are located between 
69,353,741- 69,530,721 Mb, Figure 4.5C. 
In order to determine if these are indeed independent loci, we regressed out the effect of 
the CAST/EiJ allele by adding the peak SNP, UNC16319105, as a covariate in the QTL mapping 
model. Indeed, when we regress out the peak SNP, the proximal QTL region no longer reaches 
significance and the LOD score for the peak SNP of the distal QTL region associated with the 
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phenotype increases, Figure 4.5D. The effect of the CAST/EiJ alleles between 45.3- 60 Mb is 
diminished but the Bayesian interval is unchanged, Figure 4.5E. When we performed 
association mapping, we no longer see the CAST/EiJ alleles associated with the phenotype 
between 47,929,312- 51,417,095 Mb, while the same 22 CAST/EiJ and 129S1/SvImJ shared 
alleles within the interval are still highly associated with the phenotype (LOD > 4 for the additive 
SNP model), Figure 4.5F.  
 
Identification of suggestive QTL associated with various metabolic phenotypes 
We also identified 21 QTL that reached the suggestive level of significance and these are 
summarized in Table 4.2. More than one suggestive QTL was identified for measures of baseline 
ALT, AST, and creatinine, as well as glucose: insulin ratio after dietary treatment and creatinine 
after dietary treatment. Although these results represent suggestive QTL that did not reach 
significance in our study, previous studies using the DO mice have identified and validated 
suggestive QTLs of less than 10 Mb. For example, Recla et al. identified a 3.8 Mb QTL on 
Chromosome 8 (LOD= 6, p <0.63) containing 44 positional candidates and identified Hydin as a 
high priority candidate gene associated with acute pain thermal sensitivity [100]. Of our 21 
suggestive QTL, 9 suggestive QTL have a Bayesian credible support interval of less than 10 Mb 
and 7 suggestive QTL contain less than 100 positional candidate genes. Further analysis of these 
intervals may aid us in prioritizing genes underlying these loci. Phenotyping additional DO mice 
for traits exhibiting such suggestive QTL that are trending toward genome-wide significance is 
one approach to assess the validity of suggestive QTL prior to conducting follow up studies.  
DISCUSSION 
In order to identify and take advantage of genetic differences in susceptibility to 
atherosclerosis, cardiovascular disease risk is often determined to identify risk factors known to 
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be associated with this condition. In our study, we characterized atherosclerosis and several 
cardiovascular risk factors in DO mice fed either an atherogenic or a high protein diet. In 
Chapter 2 of this thesis, I have reported QTLs identified as associated with atherosclerosis, 
glucose, insulin, triglycerides, and total cholesterol in the DO mice. In Chapter 3 of this thesis, I 
reported QTLs associated with the metabolites TMAO and choline. Here, I report the results of 
QTL mapping of 8 additional quantitative traits in this cohort of DO mice. We identified three 
significant QTL (p< 0.05) including novel loci for blood urea nitrogen and insulin resistance, as 
well as 21 suggestive loci. We discuss each of these results in turn. 
Identification of Chromosome 1 QTL associated with BUN in 6 week old mice 
The Chromosome 1 QTL associated with BUN at baseline is a prime example of the 
power of the DO to detect QTL to sub-Mb support intervals and expedite the identification of the 
underlying causal variants responsible for the observed association. We were interested in 
detecting BUN levels as a measure of kidney function in these mice to assess the effect of diet on 
overall health. In our original study design, we did not use these mice to model human kidney 
disease; therefore no validation studies of the 6 candidate genes within this interval have been 
pursued to date. However, one of these candidate genes, Esrrg, has been shown to regulate the 
morphology of renal papilla. Esrrg encodes the estrogen-receptor related gamma protein, which 
is a nuclear receptor that contains DNA-binding domains and is a transcriptional activator. Esrrg 
-/-
 knockout mice exhibit deformed renal papillae and exhibit complete postnatal lethality [160]. 
Biologically, the association of Esrrg with plasma BUN is intriguing, as renal papillae are 
composed of the collecting ducts of the nephrons where BUN is reabsorbed. Therefore, this gene 
may affect the way the nephrons are organized or possibly the permeability of the ducts. 
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Our allele effects indicated that a variant shared by the A/J, C57BL/6J, and NOD/ShiLtJ 
founder strains may be underlying this QTL. We identified only one SNP, rs32769253, matching 
the allele effects pattern that we observed, such that the strains A/J, C57BL/6J, and NOD/ShiLtJ 
share a T at this position, while the strains 129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and 
WSB/EiJ exhibit a shared T->C variant. This SNP is located in an intron of Esrrg, between 
exons 2 and 3 of the isoforms Esrrg-003 and Esrrg-004. The variant consequence is identified 
within the Sanger database as intronic, based on the Ensembl Variant Effect Predictor. However, 
it is just upstream of the coding sequences of the Esrrg-001 and Esrrg-002 isoforms, indicating it 
could play a functional role in processing of these transcripts. While there are 46 QTL previously 
identified that encompass this region of mouse Chromosome 1, none have been identified as 
associated with BUN levels or kidney function (rgd.mcw.edu). Therefore, the significant QTL 
associated with baseline BUN represents a novel locus that has not been previously 
characterized. The identification of such a refined interval associated with this phenotype 
demonstrates the power of the DO mice to expedite candidate gene testing and the determination 
of the functional significance between Esrrg and BUN levels warrants further study.  
Chromosome 8 locus associated with HOMAIR in 24 week old mice 
We identified a significant QTL on Chromosome 8 (LOD= 7.7, p< 0.05) associated with 
HOMA-IR in 24 week old mice. One positional candidate gene within the QTL interval is Fgfr1. 
Fgfr1 is a member of the fibroblast growth factor receptor family that is activated by fibroblast 
growth factors. While there are four Fgf receptors (Fgfr1-4), there are 22 Fgfs which are 
involved in a many diverse cellular functions [165]. The activity of Fgfs is regulated in part by 
ligand binding affinity and tissue distribution of Fgf receptors [166]. There are eight isoforms of 
Fgfr1 in mice and alternative mRNA splicing leads to complex tissue-specific regulation of 
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Fgfr1 function [167]. In adipocytes, Fgfr1 forms a complex with ß-Klotho and is activated by 
Fgf19 and Fgf21 [162, 163]. Fgf21 is expressed in adipose and liver tissue and it acts on adipose 
and muscle tissue primarily to release stored energy during times of stress, such as fasting. Fgf21 
stimulates glucose uptake and it has been shown that pharmacological administration of Fgf21 
lowers glucose levels. Additionally, the use of Fgfr1 agonists has recently been proposed for the 
treatment of metabolic syndrome and non-alcoholic fatty liver disease [164]. Therefore, Fgfr1 
plays a functional role in the regulation of glucose uptake at least in part via its activation by 
Fgf21 and exhibits complex regulation by multiple Fgfs. Although we have not ruled out the 41 
other positional candidates, we have identified Fgfr1 as a high priority candidate gene based on 
its known biological function in the maintenance of glucose homeostasis.  
Chromosome 9 QTL associated with change in total cholesterol exhibits complex genetic 
regulation by multiple SNP types.  
Previous reports have identified at least 6 QTL on mouse Chromosome 9 associated with 
total cholesterol, including the overlapping QTL Cq4 and Cq5, and this same region of 
Chromosome 9 has been associated with triglycerides as well [123]. In our study alone, we 
identified 4 coincident QTL on Chromosome 9 associated with measures of triglycerides and 
cholesterol with overlapping intervals and peak SNPs less than 3 Mb apart. Here, we reported the 
QTL associated with the change in total plasma cholesterol from 6 to 24 weeks. This QTL has a 
25 Mb support interval with a peak SNP at 48.3 Mb (45.3-70.3 Mb) and it includes the ApoA5-
ApoA4-ApoC3-ApoA1 gene cluster located at 46.2 Mb. 
Based on the observed founder allele effects, we identified complex genetic regulation 
with contribution from multiple variants with different strain distribution patterns within this 
interval. Using an additive SNP model, we identified two distinct regions within the QTL 
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interval that are associated with variants exhibiting different strain distribution patterns, with at 
least one CAST/EiJ-specific allele contributing to the proximal QTL region and at least one 
CAST/EiJ and 129S1/SvImJ shared allele contributing to the distal QTL region. When we 
regress out the effect of the CAST/EiJ-specific peak SNP, the effect of the CAST/EiJ alleles at 
the proximal peak is diminished; while the CAST/EiJ and 129S1/SvImJ shared alleles at the 
distal peak are still highly associated with the phenotype. Our results showed that there are two 
variants within this interval.  
Taken together, it appears that the QTL we identified on Chromosome 9 represents at 
least two separate and distinct QTLs that have different causal variants underlying the 
associations. Additionally, when we use the 2-LOD support interval to identify the boundaries of 
the QTL region, these peaks are distinct. The proximal Chromosome 9 QTL has a 2.4 Mb 
support interval (47.9-50.3 Mb) with the peak SNP located at 48.3 Mb (LOD= 7.8, p< 0.05), 
while the distal Chromosome 9 QTL has a 8.5 Mb support interval (64.7-73.2 Mb) with the peak 
SNP located at 70.2 Mb (LOD= 6.2, p< 0.63). Our results corroborate the previous findings that 
there are multiple underlying variants within this region of Chromosome 9 that are regulating 
total cholesterol. 
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Figure 4.1: Effects of HFCA diet and high protein diet on ALT, AST, and BUN levels in the 
DO mice. Mice were maintained on a synthetic diet for two weeks, fasted for four hours, and 
then phenotyped for plasma clinical chemistries at 6 weeks of age (Baseline). Following two 
weeks of synthetic diet, mice were transferred to either a high protein diet (HP) or an atherogenic 
diet (HFCA). Plasma was taken from 24-week-old mice after 18 weeks on their respective diets, 
and with four hours fasting, and then phenotyped for plasma clinical chemistries after diet 
treatment (Treated). After dietary treatment, ALT increased significantly in response to both the 
high protein diet (p <5x10
-10
) and the HFCA diet (p < 2x10
-34
). AST increased significantly in 
response to both the high protein diet (p <1x10
-15
) and the HFCA diet (p < 6x10
-13
). BUN 
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increased significantly in response to both the high protein diet (p <2x10
-19
) and the HFCA diet 
(p < 4x10
-4
). The increase in ALT corresponds to a 3-fold increase in ALT levels in response to 
the HP diet and a 7-fold increase in response to the HFCA diet (***p< 0.001, ****p< 0.0001). 
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Figure 4.2: QTL mapping of blood urea nitrogen levels in DO mice at baseline. Genome-
wide QTL scan for loci affecting plasma levels of blood urea nitrogen in 6 week old mice (A.). 
Chromosomes 1 through X are represented numerically on the x-axis and the y-axis represents 
the LOD score. The relative width of the space allotted for each Chromosome reflects the 
relative length of each Chromosome. Mice were maintained on a synthetic diet for 2 weeks and 
then phenotyped for plasma clinical chemistries at 6 weeks of age. Colored lines show 
permutation-derived significance thresholds (N=1000) at P = 0.05 (LOD=7.5, shown in red), P = 
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0.10 (LOD=7.1, shown in orange), and P = 0.63 (LOD=5.8, shown in yellow). The eight 
coefficients of the QTL model show the effect of each founder allele on the phenotype along 
Chromosome 1. Shading identifies the 95% Bayesian credible interval around the peak (B.). The 
900 kb QTL interval on Chromosome 1 contains 6 positional candidates, including the known 
genes Spata17, Gpatch2, and Esrrg, as well as the predicted genes Gm15509, Gm21710, and 
9330162B11Rik. Esrrg is a high priority candidate for this QTL.   
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Figure 4.3: Mapping of HOMA-IR in 24 week old mice. Genome-wide QTL scan for loci 
affecting calculated HOMA-IR in 24 week old mice (A.). Chromosomes 1 through X are 
represented numerically on the x-axis and the y-axis represents the LOD score. The relative 
width of the space allotted for each chromosome reflects the relative length of each chromosome.  
Plasma was taken from 24-week-old mice after 18 weeks of dietary treatment. Diet was included 
as an additive covariate in the mapping model. Colored lines show permutation-derived 
significance thresholds (N=1000) at P = 0.05 (LOD=7.5, shown in red), P = 0.10 (LOD=7.1, 
shown in orange), and P = 0.63 (LOD=5.8, shown in yellow).  The eight coefficients of the QTL  
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model show the effect of each founder haplotype on the phenotype long Chromosome 8. Shading 
identifies the 95% Bayesian credible interval around the peak (B.). There are 42 candidate genes 
within the 1.8 Mb QTL interval on Chromosome 8, including Fgfr1 (C.). 
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Figure 4.4: Chromosome 9 QTL associated with change in total plasma cholesterol exhibits 
complex genetic regulation by multiple SNP types. Genome-wide QTL scan for loci affecting 
change in cholesterol from 6 to 24 weeks of age (A.). Chromosomes 1 through X are represented 
numerically on the x-axis and the y-axis represents the LOD score. The relative width of the 
space allotted for each Chromosome reflects the relative length of each Chromosome. Mice were 
maintained on a synthetic diet for 2 weeks and then phenotyped for plasma clinical chemistries at 
6 weeks of age. Plasma was taken from 24 week old mice after 18 weeks either HFCA or high 
protein diet. Diet was included as an additive covariate in the mapping model. Colored lines 
show permutation-derived significance thresholds (N=1000) at P = 0.05 (LOD=7.5, shown in 
red), P = 0.10 (LOD=7.1, shown in orange), and P = 0.63 (LOD=5.8, shown in yellow). The 
eight coefficients of the QTL model show the effect of each founder allele on the phenotype 
along Chromosome 9. Shading identifies the 95% Bayesian credible interval around the peak. 
(B.). Using the additive SNP model, we identified SNPs associated with the phenotype. Highly 
associated SNPs are shown in red (LOD> 4). The strains that share haplotypes for associated 
SNPs are shown as grey bars (A=A/J, B=C57BL/6J, C=129S1/SvImJ, D=NOD/ShiLtJ, 
E=NZO/HiLtJ, F=CAST/EiJ, G=PWK/PhJ, H=WSB/EiJ). We identified 2 regions within the 
QTL interval that appear to be influenced by multiple variants with different strain distribution 
patterns, with CAST/EiJ alleles between 47,929,312- 51,417,095 Mb associated with the 
phenotype and CAST/EiJ and 129S1/SvImJ shared alleles between 69,353,741- 69,530,721 Mb 
associated with the phenotype (C.). Results of the genome-wide QTL scan for loci affecting 
change in total cholesterol from 6 to 24 weeks of age with the genotype of the peak SNP 
included as a covariate (D.). Allele effects along Chromosome 9 with the CAST-EiJ-specific 
peak SNP UNC16319105 included as a covariate in the model (E.). Using the additive SNP 
model, we identified SNPs associated with the phenotype. Highly associated SNPs are shown in 
red (LOD> 4). The strains that share haplotypes for associated SNPs are shown as grey bars 
(A=A/J, B=C57BL/6J, C=129S1/SvImJ, D=NOD/ShiLtJ, E=NZO/HiLtJ, F=CAST/EiJ, 
G=PWK/PhJ, H=WSB/EiJ). The effect of the CAST/EiJ alleles at the proximal peak is 
diminished; while the CAST/EiJ and 129S1/SvImJ shared alleles at the distal peak are still 
highly associated with the phenotype (F.). 
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Table 4.1: QTL associated with BUN, HOMA-IR, and change in total cholesterol (p <0.05). 
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Table 4.2: Summary of 21 suggestive QTL identified for ALT, AST, BUN, betaine, creatinine, glucose 
insulin ratio, and HOMA-IR at baseline and after dietary treatment.  
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Table 4.3: SNP analysis of the Chromosome 8 QTL associated with HOMA-IR after dietary 
treatment. 
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Table 4.4: Variants within 10 kb of the candidate gene Fgfr1.  
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CHAPTER 5: SUMMARY, DISCUSSION AND CONCLUSIONS 
 
SUMMARY AND SIGNIFICANCE 
 This dissertation focuses on improving our current understanding of the genetic 
processes, and potential therapeutically relevant targets, underlying atherosclerosis, an 
increasingly prevalent human health issue in today’s society. We have taken advantage of state 
of the art mouse resources and bioinformatics tools to refine known QTL to sub-Mb intervals, 
identify novel QTL, and even identify single causal variants underlying novel QTL. The 
Diversity Outbred Mouse population used in this study is a multi-parent outbred mouse resource 
designed to be highly informative for QTL mapping due to the inclusion of allelic variants from 
eight different inbred strains of mice and due to the high density of recombination events that 
accumulate through successive generations of outbreeding [97, 98].  
Our analyses provide information about the effects on the phenotype of each of the 
founder haplotypes at the loci we identified, allowing us to focus attention on particular variants 
with specific strain distribution patterns. The Ensembl variant consequence predictor was used to 
inform what effects the particular variants within a region may have on the phenotype. Using this 
bioinformatics-based approach, we were able to identify QTL related to phenotypic variation of 
clinically relevant complex traits associated with cardiovascular disease.  
The studies presented in this dissertation represent several novel findings that contribute 
to our understanding or the genetic architecture of atherosclerosis and complex traits related to 
CVD susceptibility. This is the first study to date to characterize atherosclerosis in the DO mice; 
122 
 
therefore the future use of the DO to study atherosclerotic lesions will be informed by the 
findings we present here. Using diet to induce lesion formation, we were able to identify 
Apobec1 as a candidate gene contributing to variation in lesion size. We also present here the 
identification of novel QTL regulating the newly discovered atherosclerosis-associated 
metabolite TMAO and the identification of Numb as a high priority positional candidate 
associated with TMAO levels in the DO mice. Additionally, we report the identification of a 
single SNP in Esrrg that is associated with variation in BUN levels in these mice.  
The identification of a single variant in a single mouse study is a level of resolution that 
had not been previously possible using traditional QTL mapping approaches. Here we have 
refined larger QTL identified in previous studies to regions containing fewer candidate genes, 
thereby expediting the identification of biologically relevant genes that are responsible for these 
associations. Additionally, we have identified novel QTL which will lead to the identification of 
new genes associated with these phenotypes, leading to a better understanding of the biological 
mechanisms of these diseases. Taken together, these findings provide a basis upon which to 
direct future studies to identify the causal genes or variants underlying the QTL not yet resolved 
at the SNP level. Here, I highlight key findings from each chapter and suggest follow up studies 
which will build upon this work.   
CONCLUSIONS AND DISCUSSION 
Identification of Apobec1 as a Candidate Gene Regulating Atherosclerosis 
Atherosclerosis is a chronic inflammatory condition that leads progressively over time to 
adverse CVD events such as heart attack or stroke [1]. CVD risk is governed by a variety of 
factors including a combination of both environmental and genetic risk factors. Certain 
individuals will be susceptible to CVD despite concerned efforts to avoid environmental risk, 
123 
 
while other individuals are less susceptible to CVD despite lifestyle choices that would seem to 
put them at higher risk for CVDs. These differences in susceptibility to disease are based on 
underlying genetic differences and we must make efforts to understand the genetics underlying 
these complex diseases [5].  
Mouse studies using inbred strains have taken advantage of the ability to tightly regulate 
the environment in which the mice are maintained in order to elucidate many genetic factors 
influencing susceptibility to CVD. Studies in mice have shown that different mouse strains 
exhibit differential susceptibility to CVD based on underlying genetic differences [40]. It is these 
genetic differences that can be exploited to better understand the complex mechanisms 
underlying such diseases and aid in the development of better therapeutic options. 
While the use of inbred mouse strains has led to the identification of over 30 
atherosclerosis-associated QTL, identification of genes associated with atherosclerosis in inbred 
crosses is limited by the high levels of homozygosity of inbred animals, such that causal variants 
not segregating in the study population will not ever be associated with the phenotype. 
Therefore, researchers have begun to use multi-parent mouse populations in order to introduce 
heterozygosity and genetic variation, including allelic variants from multiple parental strains, for 
refined QTL mapping. These features of multi-parent mouse populations, such as the DO, when 
combined with genotyping using high density arrays, such as the MegaMUGA used in the 
current study, to detect small recombination blocks allows for fine mapping of QTL intervals 
associated with complex diseases. 
The current study represents the first to quantify atherosclerosis in this newly developed 
DO mouse population. The DO mice used in this study were received in September of 2012 and 
were at Generation 11 of outbreeding. The animals were genotyped on the high density 
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MegaMUGA array, with an average marker spacing of 33 kb, and the DO genomes were 
reconstructed based on the allele intensities from the MegaMUGA array. Using this approach, 
we are able to capture the accumulation of recombination events in these animals at a rate that is 
close the theoretically expected number of events for G11 animals (390 recombinations/G11 
animal) [101].  
We fed G11 DO mice either a HFCA diet to induce atherosclerosis or a high protein, low 
fat diet not expected to be atherogenic. Based on the heterogeneous nature of the DO genomes, 
which are a mosaic of the eight founder strains, we hypothesized that DO mice fed the HFCA 
atherogenic diet would exhibit variation in susceptibility to diet-induced lesions. We measured 
lesions throughout the aortic sinuses of these mice. Indeed, we observe that none of the mice fed 
the high protein, low-fat diet developed lesions (N= 140 mice), while 76% of the mice fed the 
HFCA diet exhibited aortic lesions (N= 99 of 131 mice). We observed a large amount of 
variation in susceptibility to lesion formation among the DO animals. The lesions we observed 
ranged in both size and number, with multiple lesions observed in 65% of the mice (N=85 of 131 
mice). 
We performed QTL mapping using an additive haplotype model to identify loci 
associated with variation in atherosclerotic lesion size. We identified one highly significant QTL 
on Chromosome 6 (LOD= 10.7, p <0.05) associated with variation in lesion size in these mice. 
This region of Chromosome 6 has been previously identified as associated with atherosclerosis 
[78]. The previously identified QTL, Ath37, has a 12 Mb (116.6- 128.5 Mb) support interval 
which contains 256 genes, including Apobec1. Apobec1 is a cytidine deaminase that was first 
identified for its role in editing ApoB100 to the shorter isoform ApoB48 [168]. Apobec1 acts as 
a dimer in complex with ACF to deaminate the cytosine at position 6666 of ApoB mRNA to 
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uracil [169]. This posttranscriptional modification results in an inframe stop codon at residue 
2153 in the mature protein. In humans, tissue-specific expression of Apobec1 is responsible for 
the predominance of ApoB48 in the intestine, while ApoB100 is predominantly found in the 
liver. ApoB100 is the primary apolipoprotein of VLDL, IDL, and LDL and ApoB48 is the 
primary apolipoprotein of chylomicrons. In mice, Apobec1 edits ApoB mRNA in both the 
intestine and the liver resulting in lower levels of ApoB100-containing particles which is thought 
to contribute to the resistance to atherosclerosis in mice [170]. 
Despite its apparent role in lipid metabolism, Apobec1 was not originally implicated as a 
candidate gene underlying the Ath37 locus. Three genes, Adipor2, CD163, and A2m, were 
described as positional candidates for Ath37 based on the known biological roles for these genes 
[78]. Adipor2 was suspected because it encodes the receptor that binds the ligand adiponectin, 
which has been shown to be atheroprotective in mice [171, 172]. CD163 is a macrophage marker 
that is predictive of CVD in humans [173]. A2m is a protease inhibitor that may play a role in 
reverse cholesterol transport in humans [174]. While these genes may also play a role in 
atherosclerosis, based on the locations of Adipor2 (119,353,150- 119,417,704 Mb), CD163 
(124,304,651- 124,330,527 Mb), and A2m (121,636,173- 121,679,237 Mb) relative to the QTL 
we identified here (122,650,900- 122,735,399 Mb), these are not positional candidates for this 
QTL.  
Our atherosclerosis-associated QTL on Chromosome 6 contained only six positional 
candidate genes: Apobec1, Gdf3, Gm26168, Dppa3, Nanog, and Slc2a3. Gm26168 is a predicted 
gene with no known function; therefore we are not able to predict whether or not this gene may 
be involved with atherosclerosis without performing additional studies. Dppa3 and Nanog both 
encode transcription factors that regulate stem cell pluripotency and have not previously been 
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implicated in atherosclerotic processes [175, 176]. Slc2a3 encodes the solute carrier family 2 
member 3, which functions in glucose transport across cell membranes. While increased 
expression of Slc2a3 has been identified in atherosclerotic arteries obtained from human patients 
by one independent study [177], in mice Slc2a3 is nominally expressed in heart tissue and 
Slc2a1, Slc2a4, and Slc2a8 are the predominant isoforms in the murine heart [178]. Gdf3 
encodes the growth differentiation factor 3 and was initially a high priority candidate based on 
the previously characterized role of GDFs in cardiovascular disease [179]. Specifically, elevated 
serum levels of GDF15 have been associated with increased CVD risk in women [180].  
The additive haplotype model used to identify QTL in the DO mice estimates the effects 
of the founder alleles along each chromosome. The regression coefficients represent the additive 
genetic effects of each founder haplotype. By plotting the founder allele coefficients, we are able 
to visualize the effect that alleles contributed by each founder have within the Bayesian defined 
interval. Within the Chromosome 6 QTL interval, we observed that A/J alleles were specifically 
associated with larger lesion size compared to alleles from C57BL/6J, 129S1/SvImJ, 
NOD/ShiLtJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ. When we queried the Jackson 
Strain Expression Survey for differential expression of the genes in this locus, Apobec1 was the 
only differentially expressed gene matching the founder allele effects we observed such that A/J 
specifically expressed higher levels of Apobec1 mRNA. Therefore, based on the known 
functions of the positional candidates and the expression patterns we observed in the founder 
strain mice compared to the allele effects patterns we observed in this study population, we 
predicted that Apobec1 is the causal gene contributing to variation in lesion size.  
Interestingly, strain-specific differences in expression of Apobec1 isoforms between the 
inbred mouse strains A/J and C57BL/6J were recently identified, such that C57BL/6J mice 
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preferentially express an alternatively spliced truncated Apobec1 mRNA while A/J mice 
preferentially express a long Apobec1 transcript [119]. We exploited these findings to investigate 
whether there was a difference in the genetic regulation of each of these isoforms across the eight 
DO founder strains, which includes A/J and C57BL/6J. We identified cis-eQTL for both 
Apobec1 isoforms and we found that A/J alleles of Apobec1 were associated with increased 
expression specifically of the long isoform, but not the short isoform. These results indicate a 
potential functional relationship between isoform usage and mRNA editing efficiency of 
Apobec1 and atherosclerosis.  
Identification of Numb as a potential genetic regulator of TMAO  
Recently, several studies have identified the dietary-derived metabolite TMAO as 
associated with complex diseases in humans, including atherosclerosis and chronic kidney 
disease [134, 140, 181]. TMAO is derived from dietary choline and circulating TMAO levels 
have been identified as predictive of cardiovascular disease risk in humans [70, 132]. 
Additionally, studies of transgenic mice with an atherosclerosis-sensitizing mutation (C57BL/6J 
ApoE
-/-
) fed diets supplemented with choline or TMAO for 16 weeks showed that significant 
increases in circulating TMAO were directly correlated with lesion size independent of measures 
of plasma cholesterol, triglycerides, and glucose [70].  
It is known that TMA produced by the breakdown of choline-containing compounds by 
certain gut bacteria is transported to the liver where it is oxidized by flavin monooxygenase 
enzymes, primarily by FMO3, resulting in the production of TMAO [141]. The pivotal role of 
FMO3 in regulating TMAO levels has been well characterized in mice. Specifically, it has been 
shown that transgenic overexpression of hepatic Fmo3 results in significantly higher TMAO and 
lower TMA levels, while antisense-mediated Fmo3 knockdown results in significantly lower 
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TMAO and higher TMA levels [72]. Therefore, it would make sense that variants influencing 
Fmo3 expression or function would be identified in studies of host genetic regulation of variation 
in TMAO.  
Hartiala et al. did identify a variant in the human Fmo3 gene that was significantly 
associated with Fmo3 mRNA expression; however, this SNP did not demonstrate evidence of 
association with either plasma TMAO or CVD risk [93]. The same group did not identify the 
Fmo3 locus as associated with TMAO levels in a GWAS using HDMP mice. This could be due 
to factors such as posttranscriptional or posttranslational modifications of FMO3 playing a role 
in its regulation of TMAO, as this would not be detected at the sequence level. Alternatively, this 
could be due to a lack of variation at the Fmo3 locus across the inbred mouse strains used to 
construct the HDMP. According to the Sanger SNP database, most of the documented variation 
across the Fmo3 gene region is contributed by the four wild-derived strains SPRET/EiJ, 
CAST/EiJ, PWK/PhJ, and WSB/EiJ and one inbred mouse strain DBA/2J. DBA/2J was one of 
the inbred strains included in the HDMP [82]. Therefore, we were not surprised that we did not 
detect regulation of TMAO by variants at the Fmo3 locus in the current study and it appears that 
the regulation of TMAO by Fmo3 is complex and may be mediated by posttranscriptional or 
posttranslational modifications.  
 In the present study, we identified two novel loci influencing variation in TMAO levels 
in the DO mice, a QTL on Chromosome 14 (LOD= 8.2, p <0.05) and a QTL on Chromosome 12 
(LOD=10.0, p< 0.05). The Chromosome 14 QTL is 16.3 Mb in size and it is located in a region 
of relatively few coding genes. There are 49 positional candidates within the interval.  Based on 
the known biological roles of the positional candidate genes, we did prioritize the Krüppel-like 
factor 5, Klf5, as an attractive candidate for modulating the relationship between TMAO and 
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atherosclerosis. Klf5 is a zinc-finger transcription factor that plays a role in cell proliferation in 
the intestinal epithelium and mediates tissue remodeling in atherosclerosis [149-151]. While 
biologically Klf5 represents the most interesting candidate underlying the Chromosome 14 QTL, 
we are unable to narrow down potential candidates among the 49 positional candidate genes 
based on our allele effects at this QTL and additional studies will be required to prioritize 
candidate genes. 
The novel QTL on Chromosome 12 has a 4.6 Mb (83.6-88.2 Mb) support interval and 
contains 116 genes. In this case, CAST/EiJ and PWK/PhJ allelic contribution at the 
Chromosome 12 locus was specifically associated with lower levels of TMAO, while allelic 
contribution from A/J, C57BL/6J, 129S1/SvImJ, NOD/ShiLtJ, NZO/HiLtJ, and WSB/EiJ within 
the interval was associated with the higher TMAO levels. While the allele effects within this 
QTL interval can be used to narrow down the list of candidate genes to those genes that have 
regulatory or functional variants exhibiting the same strain distribution pattern, we identified 
15,386 of the 61,363 genotyped SNPs spanning the QTL interval as shared by and unique to 
CAST/EiJ and PWK/PhJ. It is possible that a SNP shared by CAST/EiJ and PWK/PhJ results in 
a functional variant in one of the genes within this locus. There are 78 non-synonymous coding 
SNPs in 38 genes matching our allele effects that cannot be ruled out as potential candidates.  
We also identified 259 3’ UTR SNPs, 55 5’ UTR SNPs, and 26 splice variants spanning 
the QTL interval that are shared by CAST/EiJ and PWK/PhJ and it is possible that one of these 
influences expression of the causal gene. Therefore, we compared hepatic gene expression 
among the founder strains for the genes in this region using the Jackson Strain Expression 
Survey. Based on this analysis, we identified Numb as the candidate gene that most closely 
matches the allele effects patterns we observed in the DO mice.  
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Numb is an interesting candidate because it has recently been shown to be required for 
cholesterol absorption mediated by NPC1L1 endocytosis in humans and mice and studies in 
mice have shown that dietary supplementation with TMAO reduces Npc1L1 mRNA expression 
at least in the intestines, indicating a potential functional relationship [142, 153].  
Numb is expressed in multiple tissues and it may affect processing and trafficking of 
TMAO independent of intestinal absorption. Indeed, our data focused on Numb expression from 
livers of DO and founder strain mice. Here, we measured Numb mRNA expression from liver 
tissue from the DO mice and mapped expression of this gene to a highly significant cis-eQTL on 
Chromosome 12. The colocalization of QTLs for plasma TMAO and hepatic Numb expression 
suggests that differences in Numb expression could be contributing to the variation in TMAO 
observed in the DO mice. This evidence supports a possible role for hepatic Numb in the 
regulation of TMAO levels.  
Identification of a single variant in Esrrg associated with variation in blood urea nitrogen  
In Chapter 2, we described QTL mapping of loci associated with atherosclerotic lesion 
development and cardiovascular risk factors in the DO mice. Because atherosclerosis does not 
occur spontaneously in mice, we did not expect DO mice to be susceptible to atherosclerosis. 
Therefore, we fed the mice a synthetic HFCA diet designed to induce lesion formation but 
reduce adverse pathological effects on liver and kidney function [41].  
In order to assess the impact of this diet on liver and kidney function, we measured 
plasma levels of ALT, AST, and BUN. While we were primarily interested in cardiovascular 
phenotypes, we took advantage of these data to identify QTL associated with ALT, AST, and 
BUN. While we did not identify any significant loci associated with ALT and AST, we identified 
a highly significant QTL on Chromosome 1 (LOD= 7.6, p <0.05) associated with BUN in 6 
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week old DO mice. BUN is a measure of the amount of nitrogen in the blood that comes from 
urea which is made when proteins are broken down in the body. In the presence of kidney 
dysfunction, the kidneys may not filter urea efficiently and this results in elevated BUN levels 
[182]. Based on the MGI Genes and Markers Query Form (http://www.informatics.jax.org/) 
there are no QTL in this genomic interval previously reported as associated with BUN, therefore, 
this represents a novel QTL. 
Interestingly, the allele effects at this locus indicate that a single variant contributes to 
variation in BUN levels. Based on the allele effects, allelic contribution from the founder strains 
129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and WSB/EiJ was associated with higher BUN 
levels, while allelic contribution from the A/J, C57BL/6J, and NOD/ShiLtJ founder strains was 
associated with lower BUN levels. We identified only one SNP, rs32769253, matching this allele 
effects pattern, such that the strains A/J, C57BL/6J, and NOD/ShiLtJ share a T at this position, 
while the strains 129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and WSB/EiJ exhibit a shared 
T->C variant.  
The variant consequence is identified within the Sanger database as intronic, based on the 
Ensembl Variant Effect Predictor [183]. However, it should be noted that variants may have 
different effects in different transcripts. Esrrg has four known protein-coding transcripts. The 
SNP we have identified here is located in an intron of Esrrg, between exons 2 and 3 of the 
isoforms Esrrg-003 and Esrrg-004. However, the SNP is upstream of the TSS of the Esrrg-001 
and Esrrg-002 isoforms, indicating it may affect expression of these isoforms differentially.   
Recently, Esrrg has been shown to play a role in kidney development. Esrrg encodes the 
estrogen-receptor related gamma protein, which is a nuclear receptor that contains DNA-binding 
domains and is a transcriptional activator. Esrrg is strongly expressed in the developing kidneys 
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and Esrrg
-/-
 knockout mice exhibit deformed renal papillae and a reduction in the total number of 
nephrons [160, 184]. Biologically, the association of Esrrg with plasma BUN is intriguing, as 
renal papillae are composed of the collecting ducts of the nephrons where BUN is reabsorbed 
[185].  
Based on the location and predicted effect of the single variant at the Chromosome 1 
QTL that matches our allele effects pattern and the known biological role of Esrrg in kidney 
development, we predict that this SNP influences Esrrg isoform usage and is the causal factor 
contributing to variation in BUN at this locus. The intronic SNP we have identified here may 
affect enhancer binding and expression of Esrrg isoforms, although we cannot determine the 
functional relevance of this SNP without follow up studies. Interestingly, intronic SNPs in Esrrg 
have been associated with human disease previously, indicating that isoform-specific expression 
of Esrrg plays a large role in mediating the functions of this gene [186, 187]. In order to 
understand the role of the single SNP that we identified here, we must perform additional follow 
up studies.  
FUTURE DIRECTIONS  
The data presented in this dissertation highlight the impact that the current era of mouse 
genomics has on advancing our understanding of complex human diseases. Historically, QTL 
mapping studies have sought to identify the causal genes and variants contributing to variation in 
quantitative traits related to disease states in humans. While traditional QTL experiments have 
successfully identified loci associated with complex traits, identification of causal genes and 
variants underlying these associations was often hampered by the size of the QTL intervals, 
requiring years of follow up study to determine functional associations.  
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The DO mice are a newly developed multi-parent mouse population that was specifically 
designed to be highly informative for QTL mapping. The DO mouse resource was first 
introduced in 2009 and the earliest studies of mapping quantitative traits in the DO were 
published in 2012. Since then, six additional studies have published results of QTL mapping in 
the DO mice, including the study presented in Chapter 2 of this dissertation, as summarized in 
Table 1.2.  
While highly informative, QTL mapping in multi-parent mouse populations such as the 
DO mice presents certain analytical challenges. Because the genome of each animal is a unique 
mosaic of the eight inbred founder strains, mice must be genotyped using high-density 
genotyping arrays and the haplotypes must be reconstructed to determine the contribution of 
founder alleles along the chromosomes. Genotyping mice using higher density arrays as well as 
continued improvements to haplotype reconstruction algorithms will likely continue to improve 
the mapping resolution made possible by using the DO mice. Additionally, the accumulation of 
meiotic recombination events will result in smaller and smaller haplotype blocks at each 
successive outbreeding generation of DO mice. Therefore the future of QTL studies in mice are 
likely to rely heavily on multi-parent outbred populations such as the DO and on the availability 
of analytical tools to properly perform the analysis. 
Using the DO mice in the current study, we have shown that it is possible to directly 
identify single variants associated with a phenotype, as exemplified by the identification of a 
single intronic SNP in Esrrg that is associated with variation in BUN levels. This level of 
resolution is something that was not previously possible in single experiments using inbred 
mouse strains. This is significant in that it represents a unique opportunity to expedite the 
discovery of causal genes and variants associated with complex traits. While we have shown 
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here that fine mapping of refined QTL intervals is possible using a conservative population of 
~300 DO animals, follow up studies must still be performed to validate the findings and 
definitely identify the biological relevance of the genes and variants identified by QTL mapping. 
Below, I will discuss the proposed experiments that should be conducted in order to follow up on 
and validate the major findings from the current study. 
Identification and functional significance of the A/J allele of Apobec1 in development of 
atherosclerotic lesions 
In the current study, we identified a single significant QTL on Chromosome 6 (LOD= 
10.7, p <0.05) associated with atherosclerosis. Interestingly, this region of Chromosome 6 is 
within the previously identified 12 Mb Ath37 locus; however, we have refined this region to 
~100 kb containing only 6 candidate genes. Based on the known functions of these genes, we 
identified Apobec1 as a high priority candidate for regulating lesion size and we identified a 
highly significant cis-eQTL for Apobec1, suggesting that differential expression may contribute 
to differences in lesion size.  
We found that A/J alleles at the Chromosome 6 locus were associated with larger lesion 
size, suggesting that an A/J-specific variant may contribute to larger and more extensive 
atherosclerotic lesions in these mice. Interestingly, a recent study found A/J mice preferentially 
express a specific Apobec1 isoform that alters the editing efficiency of Apobec1, such that inbred 
A/J mice exhibit higher rates of editing compared to C57BL/6J mice which preferentially 
express a truncated isoform of Apobec1 [119]. In light of the results of the present study, this 
indicates a potential functional relationship between isoform usage and mRNA editing efficiency 
of Apobec1 and atherosclerosis.  
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The previous study that identified differences in Apobec1 isoform usage between A/J and 
C57Bl/6J animals was performed using bone marrow-derived macrophages from the mice. 
Similarly, we could look for differences in Apobec1 isoform levels and differential editing of 
Apobec1 targets by isolating macrophages from animals that have A/J allelic contribution at the 
Chromosome 6 locus compared to those that have contribution from the other founders. While 
we did not collect these cells from the DO mice used in the current study, the Collaborative 
Cross mice represent a unique and valuable resource for validating our findings. The DO and CC 
mice are complementary resources and while each DO mouse has a unique genome, the CC mice 
are maintained as reproducible RILs. Therefore, we can use the CC mice to identify differences 
in Apobec1 isoform usage and editing efficiency by obtaining CC lines that have contribution 
from either A/J or one of the other founder strains at the Chromosome 6 locus we have identified 
using the DO mice. 
There are currently 48 CC RILs available, including 12 Tier 1 lines and 36 Tier 2 lines. 
Tier 1 CC lines have contribution from all 8 founders, while Tier 2 lines have allelic contribution 
from 6 to 8 of the founders used to create the DO mice. Currently, both Tier 1 and Tier 2 CC 
lines are at least 90% homozygous. Of the 48 available CC lines, there are 8 that are 
homozygous for allelic contribution from the A/J founder strain at Apobec1, including CC008, 
CC011, CC026, CC030, CC040, CC043, CC045, and CC063. There are 3 CC lines that are 
heterozygous for allelic contribution from the A/J founder at Apobec1, including CC017, CC058, 
and CC075. Of the remaining 37 CC lines, 16 are homozygous C57BL/6J at Apobec1. Based on 
the results of the current study, we would predict that those CC lines with contribution from A/J 
at Apobec1 would exhibit larger lesions in response to 18 weeks of the atherogenic diet. Based 
on the previously identified differences in isoform usage, we would predict that these lines also 
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differ in isoform usage and editing efficiency based on allelic contribution at Apobec1. We plan 
to test these hypotheses by measuring lesion size in response to the HFCA diet in CC mice and 
by isolating macrophages and measuring Apobec1 expression and editing efficiency in these 
mice. 
In addition to its known role in editing APOB, recent studies have identified at least 36 
additional mRNA targets of APOBEC1 C to U editing [122, 188]. In the present study, we found 
that APOB levels differed significantly in mice with different genotypes of the peak SNP at the 
Chromosome 6 QTL, Figure 2.12, suggesting that the A/J allele of Apobec1 may contribute to 
regulation of atherosclerosis via editing of APOB. However, it is possible that the A/J allele of 
Apobec1 influences lesion size through editing of targets other than APOB and this remains to be 
tested. Initial studies to pursue the biological mechanisms underlying the association between the 
A/J allele of Apobec1 and increased lesion size will be aimed at identifying whether the isoform-
specific variation influences APOB editing specifically. Western immunoblotting of hepatic 
APOB will be performed in order to quantify the relative amounts of APOB100 and APOB48. If 
the A/J isoform of Apobec1 is better at editing its primary target APOB, then we would expect to 
see an increase in APOB48 protein from livers of A/J mice compared to C57BL/6J mice and to 
the other 6 founder strains.  
If the results of these proposed studies suggest that A/J mice indeed harbor a causal 
variant in Apobec1 that increases atherosclerosis susceptibility, we would next identify the causal 
variant by sequencing Apobec1 in the DO and CC mice that exhibit differing founder 
contribution at the Chromosome 6 locus in order to identify sequence differences specific to A/J. 
If we are able to identify a causal variant, then we will pursue in vitro studies to determine the 
functional role of the causal variant in Apobec1. There are cell lines that actively synthesize 
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cholesterol and make serum proteins (for example FL83B) that could be used to determine the 
effect of a causal variant of Apobec1 on either editing of APOB or other target genes in vitro.  
Based on the results of these studies, we could predict the effects of overexpressing or 
knocking out the A/J allele on Apobec1 function. We could then test this by overexpressing the 
A/J variant in either C57BL/6J mice or Apobec1
-/-
 mice. The results of these studies would 
definitely identify the functional role of the A/J isoform of Apobec1 and would provide a basis 
for understanding the biological mechanism by which this variant may contribute to 
atherosclerosis susceptibility. 
Further characterization of the Chromosome 12 QTL associated with TMAO and 
validation of Numb as a functional candidate regulating TMAO levels 
In the present study, we performed QTL mapping using an additive haplotype model to 
identify loci associated with variation in TMAO levels. We identified two novel loci associated 
with this metabolite in the DO mice. The QTL interval on Chromosome 14 contains 49 
positional candidate genes, but the allele effects in this region appear complex and do not fall out 
into two distinct categories. These results indicate that there may be more than one causal variant 
influencing TMAO levels at this locus. While no follow up studies have been pursued to identify 
the causal gene underlying this QTL, we do plan to perform microarray analysis of gene 
expression from liver tissue from the DO mice used in the current study. We predict that if this 
association is the result of differences in expression of the causal gene, then this should be 
correlated with TMAO levels in this population of mice. Performing QTL mapping using the 
additive haplotype model for expression of the candidate genes to identify the presence of cis-
eQTL would also provide evidence as to which positional candidates should be pursued in follow 
up studies. 
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The Chromosome 12 QTL interval contains a total of 116 genes and the allele effects 
indicate that CAST/EiJ and PWK/PhJ contribution at the locus are specifically associated with 
lower TMAO levels, while contribution at the locus from the 6 other founder strains is associated 
with higher TMAO levels. Based on this pattern of allele effects, we queried the publicly 
available Jackson Laboratory Strain Survey for hepatic expression of candidate genes matching 
this allele effects pattern. We identified Numb as the candidate gene that most closely matches 
the allele effects patterns we observed in the DO mice. We measured Numb mRNA levels by 
QPCR and identified a highly significant cis-eQTL regulating Numb expression, indicating that 
this gene represents a high priority candidate underlying the Chromosome 12 QTL. 
Interestingly, the allele effects for the Numb cis-eQTL mirrored those of the 
Chromosome 12 QTL associated with TMAO levels, such that CAST/EiJ and PWK/PhJ allelic 
contribution at the locus was associated with higher Numb expression and lower TMAO levels. 
Consistent with these results, Numb mRNA and TMAO levels were highly negatively correlated 
in the DO mice at both 6 weeks (r= -0.65) and 24 weeks (r= -0.40).  
Functionally, Numb is an interesting gene candidate for regulation of TMAO levels 
because it plays a known role NPC1L1-mediated intestinal cholesterol absorption in both 
humans and mice. Numb is known to be expressed in multiple tissues and it may affect 
processing and trafficking of TMAO independent of intestinal absorption. Evidence has been 
published since the studies presented here were conducted that show that Numb facilitates 
NPC1L1-mediated endocytosis in both the mouse and human intestine and liver [145, 189]. A 
functional relationship has been suggested in mouse studies in which dietary supplementation 
with TMAO was shown to reduce Npc1L1 mRNA expression in the intestines, however no 
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studies to date have identified a direction functional role for NPC1L1 or NUMB in regulating 
absorption of TMA or TMAO in the liver or intestine. 
Based on our results, we observed that Numb expression is regulated by a colocalizing 
cis-eQTL at the Chromosome 12 locus and we identified a negative correlation between Numb 
expression and TMAO levels in the DO mice. Based on these results, we hypothesize that Numb 
may play a functional role in absorption of TMA and/or TMAO. If Numb expression does 
contribute to variation in TMAO levels as we have observed in the DO mice, we can validate this 
association using the CC lines. We plan to measure Numb expression and TMAO levels in 6 
week old CC mice with founder contribution at the Chromosome 12 locus from either CAST/EiJ, 
PWK/PhJ, or the other 6 founder strains. Of the 48 available CC lines, there are 8 lines available 
that are homozygous for PWK/PhJ allelic contribution at the Chromosome 12 QTL and 4 that are 
homozygous for CAST/EiJ allelic contribution at the Chromosome 12 QTL; while the other 36 
available CC lines have founder contribution from the other 6 founder strains at the locus. We 
hypothesize that CC lines with CAST/EiJ and PWK/PhJ allelic contribution at the Chromosome 
12 locus will exhibit lower TMAO levels and should also express higher levels of Numb.  
Once we have identified CC lines that exhibit high levels of TMAO and express low 
levels of Numb, we can directly test the effects of Numb expression on TMAO levels in these 
mice. We plan to transiently overexpress Numb in the livers of these mice by tail vein injection 
of an adenovirus construct (ADV-266207, Vector Biolabs) and determine the effects of 
overexpression of Numb in the liver on TMAO levels in these mice. The liver is the site of 
oxidation of TMA to TMAO and it makes sense that an endocytic protein may play a functional 
role in trafficking TMA to the site of oxidation and that variants in Numb may influence the 
efficiency of this process. 
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Another approach that will be pursued in order to better understand the potential 
functional role that Numb may play in regulating TMAO levels is a bioinformatics based 
approach aimed at identifying gene networks that are associated with the phenotype and 
identifying biologically relevant associated genes within significant networks. This approach, 
known as weighted gene co-expression network analysis or WGCNA, has been successfully used 
to identify novel pathways contributing to complex phenotypes in previous studies [84, 190]. 
Studies are currently underway to measure gene expression and differential transcript abundance 
of genes across the eight founder strain mice used to create the DO by RNA-Sequencing in our 
lab. This expression data will then be used to identify networks, or groups of genes, that are 
highly correlated with TMAO levels in the founder strain mice. Genes identified by WGCNA 
can then be further investigated using in vitro approaches and the effects can be evaluated to 
determine the potential therapeutic applications of such novel genetic associations. 
Based on the identification of Numb as a high priority candidate gene, we expect Numb to 
be contained in a module that is highly associated with TMAO levels. The identification of other 
genes in the same highly correlated network as Numb will inform us as to the potential biological 
pathway by which Numb may act to influence regulation of TMAO. For example, if we identify 
NPC1L1 in the same module, this further supports a role for NUMB-dependent NPC1L1-
mediated absorption of TMA and TMAO. Alternatively, we may identify a novel pathway by 
which Numb expression is regulated and associated with TMAO. The results of these studies 
should provide direction for experimental validation of candidate genes associated with TMAO 
levels. 
In addition to the identification of genetic regulators of TMAO, we must also consider 
the evidence that TMAO is regulated by modulation of the gut microbiome. It is known that 
141 
 
TMA produced by the breakdown of choline-containing compounds by certain gut bacteria is 
transported to the liver where it is oxidized by primarily by FMO3, resulting in the production of 
TMAO [141]. A role for the gut microbiome in regulating TMAO is therefore apparent and 
studies in humans have shown that antibiotic suppression of the gut flora prevents spikes in 
circulating TMAO levels after dietary choline challenge [142]. Most recently, a study by 
Romano et al. identified specific bacterial strains that are able to produce TMA from choline in 
vitro [191]. The identification of genes regulating both complex traits and gut microbial 
composition has been demonstrated previously [192].  Significantly, if we are able to identify 
genes as associated with TMAO that are regulating taxa or individual microbial species capable 
of producing TMA from choline, these results may provide novel therapeutic interventions for 
the treatment of multiple diseases that have been associated with elevated TMAO, including 
atherosclerosis and chronic kidney disease.  
To this end, the cohort of DO mice used in the current study is part of a meta-analysis 
that will examine the microbiome of this study population. Specifically, fecal samples were 
collected from the DO mice used in the current study at three time points and these will be used 
to conduct a full metagenomics analysis. I plan to perform QTL mapping of microbial abundance 
measured from these samples in order to identify genes that regulate the gut microbiome. It will 
be interesting to see if abundance of the intestinal microbial species identified as capable of 
producing TMA from choline maps to the same loci on Chromosome 12 or Chromosome 14 that 
we identified here as associated with TMAO levels, as this would suggest that the causal genes 
underlying these loci may regulate TMAO levels via modulation of the gut microbiome. 
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Identification of the role of the Esrrg variant rs32769253 in the regulation of BUN and 
kidney function 
In the present study, we fed mice either a HFCA diet designed to induce atherosclerotic 
lesions or a low fat, high protein control diet that was not expected to be atherogenic. In order to 
assess the impact of this diet on kidney function, we measured plasma levels of BUN which 
when elevated can indicate that the kidneys may not be functioning properly and may not be 
filtering urea efficiently. We mapped variation in this phenotype using the additive haplotype 
model and identified a highly significant QTL on Chromosome 1 associated with BUN in 6 week 
old DO mice. Interestingly, only one SNP, rs32769253, matched the allele effects patterns that 
we identified at this locus. According to the Sanger SNP database, this SNP represents a C/T 
polymorphism located in an intron of the Esrrg gene at 187,919,386 Mb (GRC Build 38). The 
strains A/J, C57BL/6J, and NOD/ShiLtJ share a T at this position, while the strains 
129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and WSB/EiJ exhibit a shared T->C variant. 
This SNP we have identified in the current study as associated with variation in BUN 
levels is identified as intronic based on its location in an intron of Esrrg, between exons 2 and 3 
of the isoforms Esrrg-003 and Esrrg-004. However, this SNP is located upstream of the TSS of 
two other known isoforms of Esrrg, Esrrg-001 and Esrrg-002, indicating it may affect 
expression of these isoforms differentially.  Therefore, we hypothesize that this variant may 
result in differential expression of certain isoforms of Esrrg. By designing primers specific for 
each isoform, we can measure expression of Esrrg isoforms in the DO mice. If this variant 
affects expression of one or both isoforms, we would expect to see a cis-eQTL at the locus with 
allele effects matching the strain distribution pattern exhibited by this SNP. 
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Additionally, we should determine whether the expression of Esrrg varies across the 
founder strains and if variation in Esrrg expression is directly or inversely associated with BUN 
levels. We hypothesis that Esrrg expression of one or more isoforms will be higher or lower in 
A/J, C57BL/6J, and NOD/ShiLtJ compared to 129S1/SvImJ, NZO/HiLtJ, CAST/EiJ, PWK/PhJ 
and WSB/EiJ. We should perform QPCR and Western immunoblotting to quantify mRNA and 
protein expression of Esrrg across the founder strains. These studies will be important to inform 
the directionality of the effect of Esrrg expression on variation in BUN levels. We could then 
confirm a direct role for this SNP in regulating the expression of Esrrg, by employing gene-
targeting technologies and site-directed mutagenesis [193, 194]. Specifically, by introducing a T 
 C in strains A/J, C57BL/6J, and NOD/ShiLtJ or a C  T in strains 129S1/SvImJ, NZO/HiLtJ, 
CAST/EiJ, PWK/PhJ/ and WSB/EiJ at this position, we can directly determine the effect of this 
SNP on Esrrg expression and BUN levels. If this variant is causal, we should see the low BUN 
expresser strains exhibit increased BUN expression and the high BUN expresser strains exhibit 
decrease BUN expression. 
Interestingly, Esrrg has been shown to regulate the morphology of renal papilla and it is 
therefore biologically plausible that a variant in Esrrg that affects kidney development might 
also influence kidney function [160]. In the current study, we were primarily interested in 
cardiovascular phenotypes and we therefore did not collect data on renal function in these mice. 
As a follow up to the findings here, studies are currently underway to measure urinary 
sodium excretion volume as a measure of renal function in an independent cohort of DO mice. 
The mice will be injected with sterile saline and then placed in metabolic cages for collection of 
urine samples and recording of sample volume at 2, 4, and 8 hour time points. The mice will be 
fasted for 4 hours and then plasma samples collected and used to measure BUN levels followed 
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by harvesting of kidney tissue to measure renal Esrrg expression. In this way, we can relate renal 
function, BUN levels, and expression of the candidate gene Esrrg in these mice. We predict that  
DO mice with reduced renal function will have elevated BUN and that these mice should exhibit 
allelic contribution at the Chromosome 1 locus from the founder strains 129S1/SvImJ, 
NZO/HiLtJ, CAST/EiJ, PWK/PhJ/ and WSB/EiJ, based on the allele effects we observed in the 
current DO study.  
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